c-MYC mRNA translation regulators and their use in cancer treatment

Abstract

The present invention relates to a novel c-MYC mRNA translation regulator, a composition containing the same, a method for preparing the same, and use thereof in cancer treatment.

Description

Technical Field

[0001] The present invention relates to a novel c-MYC mRNA translation regulator, a composition containing the same, a method for preparing the same, and its use in cancer treatment.

Background Art

[0002] Cancer is the second leading cause of death in the United States after heart disease. In the United States, one in four deaths is due to cancer. The 5-year relative survival rate for all cancer patients diagnosed between 1996 and 2003 was 66%, up from 50% in 1975-1977 (Cancer Facts & Figures American Cancer Society: Atlanta, GA (2008)). Between 2000 and 2009, the annual incidence rate of new cancer cases in men decreased by an average of 0.6% per year, while there was no change in women. Between 2000 and 2009, the mortality rate due to all cancers decreased by an average of 1.8% per year in men and 1.4% per year in women. This improvement in survival reflects the progress of early diagnosis and the improvement of treatment methods. Discovering highly effective anti-cancer agents with low toxicity is a major goal in cancer research.

[0003] The Myc family includes three major members, namely, the proto-oncogene c-Myc (cellular myelocytomatosis, abbreviated: Myc), L-Myc, and N-Myc. These three Myc homologs are involved in the early stages of carcinogenesis and metastatic spread in most human cancers. In most types of tumors, the Myc gene does not have mutations or duplications, but its mRNA and / or protein levels are increased, indicating that in cancer, overexpression of Myc is induced at the transcriptional, mRNA steady-state, and translational levels. In fact, the expression of the Myc gene is usually dependent on growth factor signaling, and the half-lives of both Myc mRNA and Myc protein are very short (30 minutes and 20 minutes, respectively) [Dang, C. V. (2012). MYC on the path to cancer. Cell 149, 22-35]. However, in tumor cells, the intracellular level of Myc is independent of such signaling and regulation, and as a result, the function of Myc deteriorates, driving intracellular and extracellular transcriptional programs that enable tumor growth and proliferation. However, for cancer to be strongly dependent on Myc activity, Myc does not necessarily have to be overexpressed. According to the study by Soucek et al. (Nature (2008) 455(7213):679-83), tumors expressing c-Myc at endogenous levels have been reported to show tumor regression upon Myc inhibition via a genetically engineered system. Therefore, treatment with Myc inhibitors is not necessarily limited to cancers that overexpress Myc. The compounds of the present invention can also be used to regulate the translation of Myc mRNA. In that case, the direct target of the compound is a protein or RNA that regulates the translation of Myc mRNA, and such Myc-dependent tumors will benefit from the therapeutic utility of the compounds of the present invention.

[0004] Myc is an important target for anticancer drugs due to its broad pathogenic importance. Dysregulation of the Myc gene is observed in a wide range of human hematological malignancies and solid tumors, particularly in breast cancer, ovarian cancer, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, prostate cancer, colon cancer, gastric cancer, primary central nervous system lymphoma, glioblastoma, medulloblastoma, melanoma, non-small cell lung cancer, germinal center-derived lymphoma, esophageal squamous cell carcinoma, osteosarcoma, bladder cancer, pancreatic cancer, and lung adenocarcinoma, among others. Recent studies have also shown that deregulation of c-MYC is associated with the development of BRAFV600E thyroid cancer, choroid plexus carcinoma, and colitis-associated cancer. In addition, amplification of the MYC gene has been observed in a significant number of cases of epithelial ovarian cancer. In the TCGA dataset, amplification of Myc occurs in several cancer types, such as breast cancer, colon cancer, pancreatic cancer, gastric cancer, and uterine cancer.

[0005] The Myc gene is a very important oncogene and is considered a driver of carcinogenesis. The MYC protein is an important transcription factor that widely targets various genes, but it remains difficult to rationally design direct Myc inhibitors. This is mainly because the MYC protein lacks structural regions suitable for therapeutic inhibition by small molecules and is considered a difficult target for drug development [BioDrugs (2019) 33:539-553].

[0006] The design and development of MYC regulators are difficult. The main reason is that the MYC protein has a disordered structure lacking pockets or grooves that function as binding sites for regulators. Inhibiting MYC transcription, inhibiting protein-protein interactions (PPIs) between MYC and its cofactors, or affecting signal transduction pathways related to MYC have previously been used as potential regulatory targets but have not been developed into drug candidates. Myc PPI inhibitors require a high target occupancy to promote efficacy and thus have not been able to show sufficient efficacy in cell-based assays or animal models. Regulators of signal transduction pathways upstream of Myc, such as mTOR regulators, have failed due to a lack of target specificity.

[0007] Nevertheless, therapeutic approaches targeting c-Myc remain unexplained. The absence of a distinct ligand-binding domain has been a major obstacle to direct inhibition, which is a difficult feature common to many potent transcriptional targets in cancer. Therefore, as outlined herein, another means of targeting Myc, namely a compound that regulates the translation of Myc mRNA, is needed. SUMMARY OF THE INVENTION MEANS FOR SOLVING THE PROBLEM

[0008] The present invention provides a compound represented by Structural Formula I, and / or I(a) to I(n) as defined below, and a compound represented by the structural formula listed in Table 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical product, or any combination thereof. In various embodiments, the compounds of the present invention are c-MYC mRNA translation regulators. In various embodiments, the compounds of the present invention are c-MYC mRNA transcription regulators. In various embodiments, the compounds of the present invention are c-MYC inhibitors. In various embodiments, the compounds of the present invention are any combination of a c-MYC mRNA transcription regulator, a c-MYC mRNA transcription regulator, and a c-MYC inhibitor.

[0009] The present invention also provides a pharmaceutical composition comprising a compound represented by Structural Formula I, and / or I(a) to I(n) as defined below, and a compound represented by the structural formula listed in Table 1, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical product, or any combination thereof.

[0010] The present invention also provides a method for the treatment, suppression, reduction of severity, reduction of onset risk, or inhibition of cancer, which comprises administering to a subject suffering from cancer a compound represented by structural formula I and / or I(a) to I(n) as defined below, and a compound represented by the structural formulas listed in Table 1, under conditions effective for the treatment, suppression, reduction of severity, reduction of onset risk, or inhibition of cancer in the subject.

[0011] The present invention also provides a method for the suppression, reduction, or inhibition of tumor growth, which comprises administering to a subject having tumor growth a compound represented by structural formula I and / or I(a) to I(n) as defined below, and a compound represented by the structural formulas listed in Table 1, under conditions effective for the suppression, reduction, or inhibition of tumor growth in the subject. In some embodiments, the tumor is cancer. In some embodiments, the subject is suffering from cancer.

[0012] The present invention also provides a method for regulating c-MYC mRNA translation in a cell, which comprises contacting the cell with a compound represented by structural formula I and / or I(a) to I(n) as defined below, and a compound represented by the structural formulas listed in Table 1, thereby regulating c-MYC mRNA translation in the cell.

[0013] The present invention also provides a method for regulating c-MYC mRNA transcription in a cell, which comprises contacting the cell with a compound represented by structural formula I and / or I(a) to I(n) as defined below, and a compound represented by the structural formulas listed in Table 1, thereby regulating c-MYC mRNA transcription in the cell. **DETAILED DESCRIPTION OF THE INVENTION**

[0014] In various embodiments, the present invention relates to a compound represented by the following structural formula (I), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0015]

Chemical formula

[0016] In the formula, X2, X3, and X4 are independently of each other CH, C(R), N (e.g., C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are independently of each other a nitrogen atom or a carbon atom; X 10 is N, CH, C(R), or C=O. Provided that when X 10 is C=O, X 11 is N (e.g., C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. Provided that when X 11 is N, X 10 is C=O; X 12is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); R5 is H, or a straight-chain or branched-chain alkyl of C1-C5 (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (for example, CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (for example, (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(a substituted or unsubstituted C3-C8 cycloalkyl) (for example, CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(a substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring) (for example, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R11 ), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 (e.g., C(O)CH3), C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl; Alternatively, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Alternatively, R6 is represented by the following structural formula B or structural formula Bi:

[0017]

Chemical formula

[0018] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Alternatively, R 12 and R 13 are both H; Alternatively, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Alternatively, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Alternatively, R 12 and R 13 are bonded to each other to form ring B; Alternatively, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Alternatively, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Alternatively, R 13 and C2 are bonded to each other to form ring E, m is 1, and R 12 is R 30 ; Alternatively, R 12 and R13 are bonded to each other to form ring B, and C1 and C3 are bonded to each other to form ring D; Ring A, ring C, and ring E are each independently a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7 is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10)(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkyl, C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, (e.g., 2 or 3-morpholine), tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidinone, imidazole, pyrazole, piperazine, piperidine, piperidin-4-ol, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, pyridine, 1-methylpyridine), R8-(substituted or unsubstituted, monocyclic, fused-ring, or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or, substituted or unsubstituted benzyl; Or, R7 is represented by the following structural formula A:

[0019]

Chemical formula

[0020] In the formula, X1 is N or O; R1 and R2 are, independently of one another, H, F, Cl, Br, I, OH, SH, CF3, C1-C5 substituted or unsubstituted alkyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted linear or branched, or C3-C8 cyclic alkoxy; or R1 and R2 are joined to one another to form =O, or a C3-C8 carbocyclic or heterocyclic ring (for example, cyclopropyl); R3 and R4 are, independently of one another, H, Me, C1-C5 substituted or unsubstituted alkyl (for example, methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (for example, (CH2)2-O-CH3), R8-N(R 10 )(R 11 (for example, (CH2)2-NH(CH3)), C3-C8 substituted or unsubstituted cycloalkyl (for example, cyclopropyl), substituted or unsubstituted 5- to 7-membered heterocyclic ring (for example, pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; or R3 and R4 are joined to one another to form a 3- to 8-membered heterocyclic ring (for example, pyrrolidine, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or R2 and R4 are joined to one another to form a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (for example, pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´ is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10, R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 and R7' are joined to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 5-membered or 6-membered carbocyclic or heterocyclic ring (e.g., piperidine, pyrrolidine, tetrahydrofuran, tetrahydropyran); R 20 is represented by the following structural formula:

[0021] [Chemical formula]

[0022] R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11)、CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight or branched alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight or branched alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight or branched haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10 (e.g., 1, 2); R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11are, independently of each other, H, OH, COOH, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl (e.g., CH2CF3), a C1-C5 straight-chain or branched-chain alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); wherein n is an integer from 0 to 4 (e.g., 1, 2).

[0023] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H.

[0024] In various embodiments, the present invention relates to a compound represented by the following structural formula I(a), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0025]

Chemical formula

[0026] wherein, X2, X3, and X4 are, independently of one another, CH, C(R), N (for example, C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom. However, when any one of X5, X6, X7, X8, and X9 is nitrogen, the respective substituents of R7´, R7´´, R7, R7´´´, and R7´´´´ do not exist; X 10 is N, CH, C(R), or C=O. However, when X 10 is C=O, X 11 is N (for example, C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. However, when X 11 is N, X 10 is C=O; X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); R5 is H, or a linear or branched alkyl of C1-C5 (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10(e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(substituted or unsubstituted C3-C8 cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecane, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 (e.g., C(O)CH3), a C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl; Or, R6 and R5 are joined to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0027]

Chemical formula

[0028] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Or, R 12 and C3 are joined to each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are joined to each other to form ring B; Or, R 12 and C1 are joined to each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are joined to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Or, R 13 and C2 are joined to each other to form ring E, m is 1, and R 12 is R 30 ; Or, R 12 and R13 are bonded to each other to form ring B, and C1 and C3 are bonded to each other to form ring D; Ring A, ring C, and ring E are each independently a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin 2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclobutane, cyclohexane); R7 is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10)(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkyl, C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, (e.g., 2- or 3-morpholine), tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidinone, imidazole, pyrazole, piperazine, piperidine, piperidin-4-ol, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, pyridine, 1-methylpyridine), R8-(substituted or unsubstituted, monocyclic, fused-ring, or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; Or, R7 is represented by the following structural formula A:

[0029]

Chemical formula

[0030] In the formula, X1 is N or O; R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms, a linear or branched alkyl having 1 to 5 carbon atoms or a cyclic haloalkyl having 3 to 8 carbon atoms, a substituted or unsubstituted linear or branched alkoxy having 1 to 5 carbon atoms, or a cyclic alkoxy having 3 to 8 carbon atoms; or, R1 and R2 are bonded to each other to form =O, or a carbocyclic or heterocyclic ring having 3 to 8 carbon atoms (e.g., cyclopropyl); R3 and R4 are, independently of each other, H, Me, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or, R2 and R4 are bonded to each other to form a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´, R7´´, R7´´´, and R7´´´´ are, independently of each other, H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10, R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 substituted or unsubstituted linear or branched alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7'' and R7 are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7' and R7''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0031]

Chemical formula

[0032] R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted linear or branched alkyl having 1 to 5 carbon atoms, a linear or branched alkoxy having 1 to 5 carbon atoms, a linear or branched haloalkyl having 1 to 5 carbon atoms, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10 (e.g., 1, 2); R9 is [CH] q , or [C] q and q is from 2 to 10; R 10 and R 11are, independently of each other, H, OH, COOH, a C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a C1-C5 substituted or unsubstituted linear or branched haloalkyl (e.g., CH2CF3), a C1-C5 linear or branched alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); wherein n is an integer from 0 to 4 (e.g., 1, 2).

[0033] In some embodiments, at least one of R7, R7´, R7´´', R7´´´, and R7´´´´ is not H. In some embodiments, at least two of R7, R7´, R7´´', R7´´´, and R7´´´´ are not H. In some embodiments, at least one of R7´, R7´´', R7´´´, and R7´´´´ is not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are different from each other. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H and are different from each other.

[0034] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12It is not S. In some embodiments, R is not H.

[0035] In various embodiments, the present invention relates to a compound represented by the following structural formula I(b), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0036]

Chemical formula

[0037] Wherein, X2, X3, and X4 are each independently CH, C(R), N (e.g., C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are each independently a nitrogen atom or a carbon atom; X 10 is N, CH, C(R), or C=O. Provided that when X 10 is C=O, X 11 is N (e.g., C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. Provided that when X 11 is N, X 10 is C=O; X 12is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); X 13 is CH2, CH(R) (for example, CH-CH3), C(R)2, or C=O; The G ring is absent or is a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (for example, cyclobutane, cyclopentane, cyclohexane); R7 is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR (for example, C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(for example, C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R10 )、C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkyl, C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, (e.g., 2- or 3-morpholine), tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidinone, imidazole, pyrazole, piperazine, piperidine, piperidin-4-ol, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, pyridine, 1-methylpyridine), R8-(substituted or unsubstituted, monocyclic, fused-ring, or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or, substituted or unsubstituted benzyl; or, R7 is represented by the following structural formula A:

[0038] [Chemical formula]

[0039] In the formula, X1 is N or O; R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted alkyl of C1-C5, a linear or branched C1-C5 or a cyclic haloalkyl of C3-C8, a substituted or unsubstituted linear or branched C1-C5, or a cyclic alkoxy of C3-C8; or, R1 and R2 are bonded to each other to form =O, or a carbocyclic or heterocyclic ring of C3-C8 (for example, cyclopropyl); R3 and R4 are, independently of each other, H, Me, a substituted or unsubstituted alkyl of C1-C5 (for example, methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (for example, (CH2)2-O-CH3), R8-N(R 10 )(R 11 (for example, (CH2)2-NH(CH3)), a substituted or unsubstituted cycloalkyl of C3-C8 (for example, cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (for example, pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (for example, pyrrolidine, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or, R2 and R4 are bonded to each other to form a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic ring or carbocyclic ring (for example, pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´ is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10, R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), C1-C5 substituted or unsubstituted straight-chain or branched alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 substituted or unsubstituted straight-chain or branched alkenyl, C1-C5 straight-chain or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched thioalkoxy, C1-C5 straight-chain or branched haloalkoxy, C1-C5 straight-chain or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 5-membered or 6-membered carbocyclic or heterocyclic ring (e.g., piperidine, pyrrolidine, tetrahydrofuran, tetrahydropyran); R 20 is represented by the following structural formula:

[0040]

Chemical formula

[0041] R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R 50 is H, R 20 , F, Cl, Br, I, OH, SH, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl, -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11)、CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight or branched alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight or branched alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight or branched haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10 (e.g., 1, 2); R9 is [CH] q , or [C] q and q is from 2 to 10; R 10 and R 11are, independently of each other, H, OH, COOH, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl (e.g., CH2CF3), a C1-C5 straight-chain or branched-chain alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); wherein n is an integer from 0 to 4 (e.g., 1, 2).

[0042] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H.

[0043] In various embodiments, the present invention relates to a compound represented by the following structural formula I(c), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0044]

Chemical formula

[0045] wherein X2, X3, and X4 are, independently of one another, CH, C(R), N (for example, C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom. However, when any one of X5, X6, X7, X8, and X9 is nitrogen, the respective substituents of R7´, R7´´, R7, R7´´´, and R7´´´´ do not exist; X 10 is N, CH, C(R), or C=O. However, when X 10 is C=O, X 11 is N (for example, C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. However, when X 11 is N, X 10 is C=O; X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); X 13 is CH2, CH(R) (for example, CH-CH3), C(R)2, or C=O; The G ring is absent or is a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (for example, cyclobutane, cyclopentane, cyclohexane); R7 is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkyl, C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, (e.g., 2- or 3-morpholine), tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidinone, imidazole, pyrazole, piperazine, piperidine, piperidin-4-ol, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, pyridine, 1-methylpyridine), R8-(substituted or unsubstituted, monocyclic, fused-ring, or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7 is represented by the following structural formula A:

[0046] [Chemical formula]

[0047] In the formula, X1 is N or O; R1 and R2 are, independently of one another, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1-C5 alkyl, a linear or branched C1-C5 or cyclic C3-C8 haloalkyl, a substituted or unsubstituted linear or branched C1-C5, or cyclic C3-C8 alkoxy; or R1 and R2 are joined to one another to form =O, or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); R3 and R4 are, independently of one another, H, Me, a substituted or unsubstituted C1-C5 alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; or R3 and R4 are joined to one another to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or R2 and R4 are joined to one another to form a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 are absent; provided that when X1 is O, R4 is absent; R7´, R7´´, R7´´´, and R7´´´´ are, independently of one another, H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10, R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 substituted or unsubstituted linear or branched alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7'' and R7 are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7' and R7''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0048] [Chemical formula]

[0049] R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted linear or branched alkyl having 1 to 5 carbon atoms, a linear or branched alkoxy having 1 to 5 carbon atoms, a linear or branched haloalkyl having 1 to 5 carbon atoms, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R 50 is H, R 20 , F, Cl, Br, I, OH, SH, N(R)2, NH(R 10 ), N(R 10 )(R 11), CF3, CN, NO2, C1-C5 substituted or unsubstituted linear or branched alkyl, C1-C5 linear or branched alkoxy, C1-C5 linear or branched haloalkyl, -R8-R 10 (e.g., (CH2)2-O-CH3), substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 ) (e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, C1-C5 substituted or unsubstituted straight or branched chain alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, C1-C5 substituted or unsubstituted straight or branched chain alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCH F2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), C1-C5 straight or branched haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-OR 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-OR 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10(e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is an integer from 1 to 10 (e.g., 1, 2); R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, OH, COOH, a substituted or unsubstituted straight-chain or branched-chain alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (e.g., cyclopropyl), a substituted or unsubstituted straight-chain or branched-chain haloalkyl having 1 to 5 carbon atoms (e.g., CH2CF3), a straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are bonded to each other to form a substituted or unsubstituted heterocyclic ring having 3 to 8 members (e.g., piperazine, piperidine); In the formula, n is an integer from 0 to 4 (e.g., 1, 2).

[0050] In some embodiments, at least one of R7, R7′, R7″, R7″′, and R7″″′ is not H. In some embodiments, at least two of R7, R7′, R7″, R7″′, and R7″″′ are not H. In some embodiments, at least one of R7′, R7″, R7″′, and R7″″′ is not H. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″′ are not H. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″′ are different from each other. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″′ are not H and are different from each other.

[0051] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H.

[0052] In various embodiments, the present invention relates to a compound represented by the following structural formula I(d), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0053]

Chemical formula

[0054] wherein, X2, X3, and X4 are, independently of one another, CH, C(R), N (for example, C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom; X 10 is N, CH, C(R), or C=O. However, when X 10 is C=O, X 11 is N (for example, C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. However, when X 11 is N, X 10 is C=O; X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); The F ring is absent or is a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (for example, pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms, a linear or branched alkyl having 1 to 5 carbon atoms or a cyclic haloalkyl having 3 to 8 carbon atoms, a substituted or unsubstituted linear or branched alkoxy having 1 to 5 carbon atoms, or a cyclic alkoxy having 3 to 8 carbon atoms; or, R1 and R2 are bonded to each other to form =O, or a carbocyclic or heterocyclic ring having 3 to 8 carbon atoms (e.g., cyclopropyl); or, R2 and R4 are bonded to each other to form the F ring defined above (e.g., pyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, pyrimidine, triazole, oxadiazole, pyrazole). However, when the F ring is an aromatic ring, R1 and / or R3 do not exist; R3 and R4 are, independently of each other, H, Me, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (e.g., cyclopropyl), a substituted or unsubstituted heterocyclic ring having 5 to 7 members (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; or, R3 and R4 are bonded to each other to form a heterocyclic ring having 3 to 8 members (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); R5 is H, or a linear or branched alkyl having 1 to 5 carbon atoms (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R10 ,-O-R8-R 10 , R8-(substituted or unsubstituted C3-C8 cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R11 )、 COOH, -C(O)Ph, C(O)O-R 10 、 R8-C(O)-R 10 、 C(O)H, C(O)-R 10 (e.g., C(O)CH3), a C1-C5 straight or branched chain C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10)、C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 substituted or unsubstituted linear or branched alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocycle (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl; Alternatively, R6 and R5 are joined to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Alternatively, R6 is represented by the following structural formula B or structural formula Bi:

[0055]

Chemical formula

[0056] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Alternatively, R 12 and R 13 are both H; Alternatively, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Alternatively, R 12 and C3 are joined to each other to form ring A, and R 13 is R 30 ; Alternatively, R 12 and R 13 are joined to each other to form ring B; Alternatively, R 12 and C1 are joined to each other to form ring C, and R 13 is R 30 ; Alternatively, C1 and C3 are joined to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Alternatively, R 13 and C2 are joined to each other to form ring E, m is 1, and R 12 is R 30 ; Alternatively, R 12 and R13 are bonded to each other to form ring B, and C1 and C3 are bonded to each other to form ring D; Ring A, ring C, and ring E are, independently of one another, a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclobutane, cyclohexane); R7´ is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11)、B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 )、CH(CF3)(NH-R 10 )、a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; R 20 is represented by the following structural formula:

[0057]

Chemical formula

[0058] R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11)、CF3, CN, NO2, C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, C1-C5 substituted or unsubstituted linear or branched alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), C1-C5 linear or branched haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), substituted or unsubstituted aryl (e.g., phenyl), or substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, C1-C5 substituted or unsubstituted linear or branched alkyl, C1-C5 linear or branched alkoxy, C1-C5 linear or branched haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R10 、 -R8-R 10 、 a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; Each R8, independently of one another, is [CH2] p and p is from 1 to 10 (for example, 1, 2); R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11 are, independently of one another, H, OH, COOH, a substituted or unsubstituted linear or branched C1-C5 alkyl (for example, methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a substituted or unsubstituted C3-C8 cycloalkyl (for example, cyclopropyl), a substituted or unsubstituted linear or branched C1-C5 haloalkyl (for example, CH2CF3), a linear or branched C1-C5 alkoxy (for example, O-CH3), R 20 C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); wherein n is an integer from 0 to 4 (for example, 1, 2).

[0059] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H. In some embodiments, when R1 and R2 are joined to each other to form C=O, at least one of X2, X3, X4, and X 10 is not CH.

[0060] In various embodiments, the present invention relates to a compound represented by the following structural formula I(e), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0061]

Chemical formula

[0062] Wherein, X2, X3, and X4 are each independently CH, C(R), N (e.g., C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are each independently a nitrogen atom or a carbon atom. Provided that when any one of X5, X6, X8, and X9 is nitrogen, the respective substituents of R7´, R7´´, R7´´´, and R7´´´´ do not exist; X 10 is N, CH, C(R), or C=O. Provided that when X 10 is C=O, X 11 is N (e.g., C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. Provided that when X 11 is N, X 10 is C=O; X 12is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); The F ring is absent or is a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (for example, pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1-C5 alkyl, a linear or branched C1-C5 or a cyclic C3-C8 haloalkyl, a substituted or unsubstituted linear or branched C1-C5, or a cyclic C3-C8 alkoxy; or R1 and R2 are bonded to each other to form =O, or a C3-C8 carbocyclic or heterocyclic ring (for example, cyclopropyl); or R2 and R4 are bonded to each other to form the F ring as defined above (for example, pyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, pyrimidine, triazole, oxadiazole, pyrazole). However, when the F ring is an aromatic ring, R1 and / or R3 are absent; R3 and R4 are, independently of each other, H, Me, a substituted or unsubstituted C1-C5 alkyl (for example, methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (for example, (CH2)2-O-CH3), R8-N(R 10 )(R 11)(e.g., (CH2)2-NH(CH3)), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or, R 20 is; or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); R5 is H, or a C1-C5 straight-chain or branched-chain alkyl (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecane, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ) (e.g., (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11)、COOH, -C(O)Ph, C(O)O-R 10 、R8-C(O)-R 10 、C(O)H, C(O)-R 10 (e.g., C(O)CH3), a straight-chain or branched C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10)、C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl; Or, R6 and R5 are combined with each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (for example, azepane, piperazine, 2-(piperazin-1-yl)acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0063]

Chemical formula

[0064] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (for example, ethyl, trifluoroethyl); Or, R 12 and C3 are combined with each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are combined with each other to form ring B; Or, R 12 and C1 are combined with each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are combined with each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Or, R 13 and C2 are combined with each other to form ring E, m is 1, and R 12 is R 30 ; Or, R 12 and R13 are combined with each other to form ring B, and C1 and C3 are combined with each other to form ring D; Ring A, ring C, and ring E are each independently a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin 2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7′, R7″, R7″′, and R7″″ are each independently H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0065]

Chemical formula

[0066] R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted linear or branched C1-C5 alkyl, a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; Each R8 is, independently of one another, [CH2] p , and p is an integer from 1 to 10 (for example, 1, 2); R9 is [CH] q , or [C] q , and q is an integer from 2 to 10; R 10 and R 11 are, independently of one another, H, OH, COOH, a substituted or unsubstituted linear or branched C1-C5 alkyl (for example, methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a substituted or unsubstituted C3-C8 cycloalkyl (for example, cyclopropyl), a substituted or unsubstituted linear or branched C1-C5 haloalkyl (for example, CH2CF3), a linear or branched C1-C5 alkoxy (for example, O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); In the formula, n is an integer from 0 to 4 (for example, 1, 2).

[0067] In some embodiments, at least one of R7′, R7″′, R7″″, and R7″″″ is not H. In some embodiments, at least two of R7′, R7″′, R7″″, and R7″″″ are not H. In some embodiments, at least two of R7′, R7″′, R7″″, and R7″″″ are different from each other. In some embodiments, at least two of R7′, R7″′, R7″″, and R7″″″ are not H and are different from each other.

[0068] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H. In some embodiments, when R1 and R2 are joined to each other to form C═O, at least one of X2, X3, X4, and X 10 is not CH.

[0069] In various embodiments, the present invention relates to a compound represented by the following structural formula I(f), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0070]

Chemical formula

[0071] Wherein, X2, X3, and X4 are, independently of one another, CH, C(R), N (for example, C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom. However, when any one of X5, X6, X8, and X9 is nitrogen, each substituent of R7´, R7´´, R7´´´, and R7´´´´ does not exist; X 10 is N, CH, C(R), or C=O. However, when X 10 is C=O, X 11 is N (for example, C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. However, when X 11 is N, X 10 is C=O; X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); X 13 is CH2, CH(R) (for example, CH-CH3), C(R)2, or C=O; The G ring is absent or is a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (for example, cyclobutane, cyclopentane, cyclohexane); The F ring is absent or is a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are each independently H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms, a linear or branched C1-C5 or cyclic haloalkyl having 3 to 8 carbon atoms, a substituted or unsubstituted linear or branched C1-C5 or cyclic alkoxy having 3 to 8 carbon atoms; or R1 and R2 are bonded to each other to form =O or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); or R2 and R4 are bonded to each other to form the F ring as defined above (e.g., pyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, pyrimidine, triazole, oxadiazole, pyrazole). However, when the F ring is an aromatic ring, R1 and / or R3 are absent; R3 and R4 are each independently H, Me, a substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH(CH3)), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; or R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); R7′, R7″, R7″′, and R7″″ are, independently of one another, H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; Alternatively, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0072] [Chemical formula]

[0073] R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted linear or branched alkyl having 1 to 5 carbon atoms, a linear or branched alkoxy having 1 to 5 carbon atoms, a linear or branched haloalkyl having 1 to 5 carbon atoms, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; R 50 is H, R 20 , F, Cl, Br, I, OH, SH, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted linear or branched alkyl having 1 to 5 carbon atoms, a linear or branched alkoxy having 1 to 5 carbon atoms, a linear or branched haloalkyl having 1 to 5 carbon atoms, -R8-R 10(For example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (for example, phenyl), a substituted or unsubstituted heteroaryl (for example, pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(for example, C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted straight-chain or branched-chain alkyl having 1 to 5 carbon atoms (for example, methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms, cyclopropyl, a substituted or unsubstituted straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (for example, methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a straight-chain or branched-chain haloalkyl having 1 to 5 carbon atoms (for example, CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (for example, CH2-Ph), -R8-O-R8-O-R 10 (for example, (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (for example, O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (for example, (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2,3,4-pyridine)); Each R8 is independently of one another, [CH2]p where p is from 1 to 10 (for example, 1, 2); R9 is [CH] q or [C] q where q is from 2 to 10; R 10 and R 11 are, independently of each other, H, OH, COOH, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (for example, methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a C3-C8 substituted or unsubstituted cycloalkyl (for example, cyclopropyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl (for example, CH2CF3), a C1-C5 straight-chain or branched-chain alkoxy (for example, O-CH3), R 20 C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); wherein n is an integer from 0 to 4 (for example, 1, 2).

[0074] In some embodiments, at least one of R7′, R7″′, R7″″, and R7″″″ is not H. In some embodiments, at least two of R7′, R7″′, R7″″, and R7″″″ are not H. In some embodiments, at least two of R7′, R7″′, R7″″, and R7″″″ are different from each other. In some embodiments, at least two of R7′, R7″′, R7″″, and R7″″″ are not H and are different from each other.

[0075] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X11 is N; or, X 12 is not S. In some embodiments, R is not H.

[0076] In various embodiments, the present invention relates to a compound represented by the following structural formula I(g), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0077] [Chemical formula]

[0078] In the formula, X2, X3, and X4 are, independently of each other, CH, C(R), N (e.g., C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are, independently of each other, a nitrogen atom or a carbon atom. Provided that when any one of X5, X6, X8, and X9 is nitrogen, the respective substituents of R7′, R7″, R7″′, and R7″″ do not exist; X 10 is N, CH, C(R), or C=O. Provided that when X 10 is C=O, X 11 is N (e.g., C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. Provided that when X11 When N is N, X 10 is C=O; X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (e.g., N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); X 14 is S, O, N, or CH. However, when X 14 is CH, the F ring does not exist, and when X 14 is S or O, R3 does not exist; The F ring does not exist or is a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1-C5 alkyl, a linear or branched C1-C5 or a cyclic C3-C8 haloalkyl, a substituted or unsubstituted linear or branched C1-C5, or a cyclic C3-C8 alkoxy; or R1 and R2 are bonded to each other to form =O, or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); or R2 and R4 are bonded to each other to form the F ring defined above (e.g., pyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, pyrimidine, triazole, oxadiazole, pyrazole). However, when the F ring is an aromatic ring, R1 and / or R3 do not exist; R3 and R4 are, independently of each other, H, Me, a substituted or unsubstituted C1-C5 alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); X 14 is S or O, and R3 does not exist; R5 is H, or a linear or branched C1-C5 alkyl (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ) (e.g., (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11)、COOH, -C(O)Ph, C(O)O-R 10 、R8-C(O)-R 10 、C(O)H, C(O)-R 10 (e.g., C(O)CH3), a C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted chloroalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl; Alternatively, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Alternatively, R6 is represented by the following structural formula B or structural formula Bi:

[0079]

Chemical formula

[0080] wherein, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Alternatively, both R 12 and R 13 are H; Alternatively, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Alternatively, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Alternatively, R 12 and R 13 are bonded to each other to form ring B; Alternatively, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Alternatively, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Alternatively, R 13 and C2 are bonded to each other to form ring E, m is 1, and R 12 is R 30 ; Alternatively, R 12 and R13 are bonded to each other to form ring B, and C1 and C3 are bonded to each other to form ring D; Ring A, ring C, and ring E are each independently a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclobutane, cyclohexane); R7′, R7″, R7″′, and R7″″ are each independently H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0081]

Chemical formula

[0082] R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted linear or branched C1-C5 alkyl, a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; Each R8 is independently of one another, [CH2] p and p is an integer from 1 to 10 (for example, 1, 2); R9 is [CH] q , or [C] q and q is an integer from 2 to 10; R 10 and R 11 are independently of one another, H, OH, COOH, a substituted or unsubstituted linear or branched C1-C5 alkyl (for example, methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a substituted or unsubstituted C3-C8 cycloalkyl (for example, cyclopropyl), a substituted or unsubstituted linear or branched C1-C5 haloalkyl (for example, CH2CF3), a linear or branched C1-C5 alkoxy (for example, O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to one another to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); In the formula, n is an integer from 0 to 4 (for example, 1, 2).

[0083] In some embodiments, at least one of R7′, R7″, R7″′, and R7″″′ is not H. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″′ are not H. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″′ are different from each other. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″′ are not H and are different from each other.

[0084] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H. In some embodiments, when R1 and R2 are joined to each other to form C═O, at least one of X2, X3, X4, and X 10 is not CH.

[0085] In various embodiments, the present invention relates to a compound represented by the following structural formula I(h), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0086]

Chemical formula

[0087] wherein, X2, X3, and X4 are, independently of one another, CH, C(R), N (for example, C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom. However, when any one of X5, X6, X8, and X9 is nitrogen, the respective substituents of R7´, R7´´, R7´´´, and R7´´´´ do not exist; X 10 is N, CH, C(R), or C=O. However, when X 10 is C=O, X 11 is N (for example, C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. However, when X 11 is N, X 10 is C=O; X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); X 13 is CH2, CH(R) (for example, CH-CH3), C(R)2, or C=O; X 14 is S, O, N, or CH. However, when X 14 is CH, the F ring does not exist, and X 14When it is S or O, R3 does not exist; The G ring either does not exist or is a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclobutane, cyclopentane, cyclohexane); The F ring either does not exist or is a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are each independently H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1-C5 alkyl, a linear or branched C1-C5 or cyclic C3-C8 haloalkyl, a substituted or unsubstituted linear or branched C1-C5 or cyclic C3-C8 alkoxy; Or, R1 and R2 are bonded to each other to form =O or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); Or, R2 and R4 are bonded to each other to form the F ring defined above (e.g., pyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, pyrimidine, triazole, oxadiazole, pyrazole). However, when the F ring is an aromatic ring, R1 and / or R3 do not exist; R3 and R4 are each independently H, Me, a substituted or unsubstituted C1-C5 alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH(CH3)), a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 is; Alternatively, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); R7′, R7″, R7″′, and R7″″ are each independently H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; Alternatively, R7' and R7'' are joined to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7''' and R7'''' are joined to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0088] [Chemical formula]

[0089] R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; R 50 is H, R 20 , F, Cl, Br, I, OH, SH, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl, -R8-R 10(For example, (CH2)2-O-CH3), a substituted or unsubstituted aryl (for example, phenyl), a substituted or unsubstituted heteroaryl (for example, pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(for example, C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted C1-C5 straight-chain or branched-chain alkyl (for example, methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, a substituted or unsubstituted C1-C5 straight-chain or branched-chain alkoxy (for example, methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight-chain or branched-chain haloalkyl (for example, CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (for example, CH2-Ph), -R8-O-R8-O-R 10 (for example, (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (for example, O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (for example, (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2,3,4-pyridine)); Each R8 is independently of one another, [CH2]p where p is from 1 to 10 (for example, 1, 2); R9 is [CH] q or [C] q where q is from 2 to 10; R 10 and R 11 are, independently of each other, H, OH, COOH, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (for example, methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a C3-C8 substituted or unsubstituted cycloalkyl (for example, cyclopropyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl (for example, CH2CF3), a C1-C5 straight-chain or branched-chain alkoxy (for example, O-CH3), R 20 C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (for example, piperazine, piperidine); wherein n is an integer from 0 to 4 (for example, 1, 2).

[0090] In some embodiments, at least one of R7′, R7″′, R7″″, and R7″″″ is not H. In some embodiments, at least two of R7′, R7″′, R7″″, and R7″″″ are not H. In some embodiments, at least two of R7′, R7″′, R7″″, and R7″″″ are different from each other. In some embodiments, at least two of R7′, R7″′, R7″″, and R7″″″ are not H and are different from each other.

[0091] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X11 is N; or, X 12 is not S. In some embodiments, R is not H.

[0092] In various embodiments, the present invention relates to a compound represented by the following structural formula I(i), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0093]

Chemical formula

[0094] In the formula, X2, X3, and X4 are, independently of each other, CH, C(R), N (e.g., C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are, independently of each other, a nitrogen atom or a carbon atom. Provided that when any one of X5, X6, X8, and X9 is nitrogen, the respective substituents of R7´, R7´´, R7´´´, and R7´´´´ do not exist; X 10 is N, CH, C(R), or C=O. Provided that when X 10 is C=O, X 11 is N (e.g., C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. Provided that when X11 When N is N, X 10 is C=O; X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); R5 is H, or a straight-chain or branched-chain alkyl of C1-C5 (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (for example, CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (for example, (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused ring, or spiro ring 3-10 membered heterocyclic ring) (e.g., (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11)、COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 (e.g., C(O)CH3), C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl; Alternatively, R6 and R5 are joined to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Alternatively, R6 is represented by the following structural formula B or structural formula Bi:

[0095]

Chemical formula

[0096] wherein, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Alternatively, both R 12 and R 13 are H; Alternatively, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Alternatively, R 12 and C3 are joined to each other to form ring A, and R 13 is R 30 ; Alternatively, R 12 and R 13 are joined to each other to form ring B; Alternatively, R 12 and C1 are joined to each other to form ring C, and R 13 is R 30 ; Alternatively, C1 and C3 are joined to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Alternatively, R 13 and C2 are joined to each other to form ring E, m is 1, and R 12 is R 30 ; Alternatively, R 12 and R13 C1 and C3 are bonded to each other to form ring D; Ring A, ring C, and ring E are each independently a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7′, R7″, R7″′, and R7″″ are each independently H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7'' and R7 are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7 and R7''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0097]

Chemical formula

[0098] R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted straight-chain or branched-chain alkyl having 1 to 5 carbon atoms (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms, cyclopropyl, a substituted or unsubstituted straight-chain or branched-chain alkoxy having 1 to 5 carbon atoms (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a straight-chain or branched-chain haloalkyl having 1 to 5 carbon atoms (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), substituted or unsubstituted aryl (e.g., phenyl), or substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, C1-C5 straight-chain or branched-chain alkoxy, C1-C5 straight-chain or branched-chain haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 50 is H, R 20 , F, Cl, Br, I, OH, SH, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, C1-C5 straight-chain or branched-chain alkoxy, C1-C5 straight-chain or branched-chain haloalkyl, -R8-R 10 (e.g., (CH2)2-O-CH3), substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10 (e.g., 1, 2); R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11are, independently of one another, H, OH, COOH, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl (e.g., CH2CF3), a C1-C5 straight-chain or branched-chain alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); wherein n is an integer from 0 to 4 (e.g., 1, 2).

[0099] In some embodiments, at least one of R7, R7´, R7´´', R7´´´, and R7´´´´ is not H. In some embodiments, at least two of R7, R7´, R7´´', R7´´´, and R7´´´´ are not H. In some embodiments, at least one of R7´, R7´´', R7´´´, and R7´´´´ is not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are different from each other. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H and are different from each other.

[0100] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, R is not H.

[0101] In various embodiments, the present invention relates to a compound represented by the following structural formula I(j), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0102]

Chemical formula

[0103] In the formula, X2, X3, and X4 are each independently CH, C(R), N (e.g., C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X5, X6, X7, X8, and X9 are each independently a nitrogen atom or a carbon atom. However, when any one of X5, X6, X8, and X9 is nitrogen, the respective substituents of R7´, R7´´, R7´´´, and R7´´´´ do not exist; X 10 is N, CH, C(R), or C=O. However, when X 10 is C=O, X 11 is N (e.g., C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. However, when X 11 is N, X 10 is C=O; X 12is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); R5 is H, or a straight-chain or branched alkyl of C1-C5 (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (for example, CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (for example, (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(a substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring) (for example, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R11 ), R8-N(R 10 )(R 11 )(for example, (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R 10 )(R 11 (for example, (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 (for example, C(O)CH3), C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), a substituted or unsubstituted aryl, a substituted or unsubstituted R8-aryl (e.g., benzyl), or a substituted or unsubstituted benzyl; Or, R6 and R5 are combined with each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (for example, azepane, piperazine, 2-(piperazin-1-yl)acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0104]

Chemical formula

[0105] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (for example, ethyl, trifluoroethyl); Or, R 12 and C3 are combined with each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are combined with each other to form ring B; Or, R 12 and C1 are combined with each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are combined with each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Or, R 13 and C2 are combined with each other to form ring E, m is 1, and R 12 is R 30 ; Or, R 12 and R13 C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are each independently a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); The B ring is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin 2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7′, R7″, R7″′, and R7″″ are each independently H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7'' and R7 are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7 and R7''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0106]

Chemical formula

[0107] R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), substituted or unsubstituted aryl (e.g., phenyl), or substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, C1-C5 straight-chain or branched-chain alkoxy, C1-C5 straight-chain or branched-chain haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; Each R8 is independently [CH2] p , and p is 1 to 10 (e.g., 1, 2); R9 is [CH] q , or [C] q , and q is 2 to 10; R 10 and R 11 are independently H, OH, COOH, C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl (e.g., CH2CF3), C1-C5 straight-chain or branched-chain alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; Or, R 10 and R 11 are bonded to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); In the formula, n is an integer from 0 to 4 (for example, 1, 2).

[0108] In some embodiments, at least one of R7, R7´, R7´´', R7´´´, and R7´´´´ is not H. In some embodiments, at least two of R7, R7´, R7´´', R7´´´, and R7´´´´ are not H. In some embodiments, at least one of R7´, R7´´', R7´´´, and R7´´´´ is not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are different from each other. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H and are different from each other.

[0109] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H.

[0110] In various embodiments, the present invention relates to a compound represented by the following structural formula I(k), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (for example, deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0111]

Chemical formula

[0112] In the formula, The W ring can be an aromatic ring or a non-aromatic ring. When the W ring is an aromatic ring, X2, X3, and X4 are, independently of one another, CH, C(R), N (for example, C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), or C(OH)); X 15 is C; When the W ring is a non-aromatic ring, X2, X3, and X4 are, independently of one another, CH2, CH(R), C(R)2, NH, N(R), O, S, S=O, or SO2 (for example, CH2); X 15 is CH, C(R), or N (for example, CH, N); X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom. However, when any one of X5, X6, X7, X8, and X9 is nitrogen, each of the substituents R7´, R7´´, R7, R7´´´, and R7´´´´ does not exist; X 10 is N, CH, C(R), or C=O. However, when X 10 is C=O, X 11 is N (for example, C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. However, when X 11 is N, X 10 is C=O; The W´ ring can be an aromatic ring or a non-aromatic ring. When the W´ ring is an aromatic ring, X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (e.g., N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); When the W' ring is a non-aromatic ring, X 12 is CH=CH, CH=CH(R), C(R)=CH, OCH2, CH2O, SCH2, CH2S, CH=N, C(R)=N, N=CH, N=C(R); R5 is H, or a straight-chain or branched-chain alkyl of C1-C5 (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3-10 membered heterocyclic ring) (e.g., (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecane, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ) (e.g., (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R 10 )(R 11 ) (e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11)、COOH, -C(O)Ph, C(O)O-R 10 、R8-C(O)-R 10 、C(O)H, C(O)-R 10 (e.g., C(O)CH3), C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), a substituted or unsubstituted aryl, a substituted or unsubstituted R8-aryl (e.g., benzyl), or a substituted or unsubstituted benzyl; Alternatively, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Alternatively, R6 is represented by the following structural formula B or structural formula Bi:

[0113]

Chemical formula

[0114] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Alternatively, both R 12 and R 13 are H; Alternatively, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Alternatively, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Alternatively, R 12 and R 13 are bonded to each other to form ring B; Alternatively, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Alternatively, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Alternatively, R 13 and C2 are bonded to each other to form ring E, m is 1, and R 12 is R 30 ; Alternatively, R 12 and R13 are bonded to each other to form ring B, and C1 and C3 are bonded to each other to form ring D; Ring A, ring C, and ring E are each independently a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7 is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10 , R8-(C3-C8 cycloalkyl), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10)(R 11 )、B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR (e.g., C(O)NH(CH3)), C(O)N(R 10 )(R 11 )(e.g., C(O)NH(CH3), C(O)NH(CH2CH2OCH3), C(O)NH(CH2CH2OH)), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methylimidazole, methyl, ethyl), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkyl, C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclopropanol, cyclohexyl), substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, (e.g., 2- or 3-morpholine), tetrahydropyran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidinone, imidazole, pyrazole, piperazine, piperidine, piperidin-4-ol, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, pyridine, 1-methylpyridine), R8-(substituted or unsubstituted, monocyclic, fused-ring, or spiro-ring 3- to 8-membered heterocyclic ring), substituted or unsubstituted aryl, or, substituted or unsubstituted benzyl; Or, R7 is represented by the following structural formula A:

[0115] [Chemical formula]

[0116] In the formula, X1 is N or O; R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1-C5 alkyl, a linear or branched C1-C5 or cyclic C3-C8 haloalkyl, a substituted or unsubstituted linear or branched C1-C5, or cyclic C3-C8 alkoxy; or, R1 and R2 are bonded to each other to form =O, or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); R3 and R4 are, independently of each other, H, Me, a substituted or unsubstituted C1-C5 alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 (e.g., (CH2)2-NH(CH3)), a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or, R2 and R4 are bonded to each other to form a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole). However, when the ring is an aromatic ring, R1 and / or R3 do not exist; however, when X1 is O, R4 does not exist; R7´, R7´´, R7´´´, and R7´´´´ are, independently of each other, H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10, R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), C1-C5 substituted or unsubstituted straight-chain or branched alkyl (e.g., isopropyl, methyl, ethyl), C1-C5 substituted or unsubstituted straight-chain or branched alkenyl, C1-C5 straight-chain or branched or C3-C8 cyclic haloalkyl (e.g., CHF2), C1-C5 straight-chain or branched or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), C1-C5 straight-chain or branched thioalkoxy, C1-C5 straight-chain or branched haloalkoxy, C1-C5 straight-chain or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7'' and R7 are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7' and R7''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0117] [Chemical formula]

[0118] R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 ), C(O)CH3, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11)、CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10 (e.g., 1, 2); R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11are, independently of each other, H, OH, COOH, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl (e.g., CH2CF3), a C1-C5 straight-chain or branched-chain alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); wherein n is an integer from 0 to 4 (e.g., 1, 2).

[0119] In some embodiments, at least one of R7, R7′, R7″, R7″′, and R7″″ is not H. In some embodiments, at least two of R7, R7′, R7″, R7″′, and R7″″ are not H. In some embodiments, at least one of R7′, R7″, R7″′, and R7″″ is not H. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″ are not H. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″ are different from each other. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″ are not H and are different from each other.

[0120] In some embodiments, the W ring is an aromatic ring and at least one of X2, X3, and X4 is C(R). In some embodiments, the W ring is an aromatic ring and X 11 is N. In some embodiments, the W ring is an aromatic ring and X 12It is not S. In some embodiments, the W ring is an aromatic ring, and at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H. In some embodiments, when both the W ring and the W' ring are aromatic rings, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S.

[0121] In various embodiments, the present invention relates to a compound represented by the following structural formula I(l), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0122]

Chemical formula

[0123] Wherein, The W ring can be an aromatic ring or a non-aromatic ring. When the W ring is an aromatic ring, X2, X3, and X4 are, independently of each other, CH, C(R), N (e.g., C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X 15 is C; When the W ring is a non-aromatic ring, X2, X3, and X4 are, independently of one another, CH2, CH(R), C(R)2, NH, N(R), O, S, S=O, or SO2 (for example, CH2); X 15 is CH, C(R), or N (for example, CH, N); X5, X6, X7, X8, and X9 are, independently of one another, a nitrogen atom or a carbon atom. However, when any one of X5, X6, X7, X8, and X9 is nitrogen, the respective substituents of R7´, R7´´, R7, R7´´´, and R7´´´´ do not exist; X 10 is N, CH, C(R), or C=O. However, when X 10 is C=O, X 11 is N (for example, C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. However, when X 11 is N, X 10 is C=O; The W´ ring can be an aromatic ring or a non-aromatic ring. When the W´ ring is an aromatic ring, X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); When the W´ ring is a non-aromatic ring, X 12 is CH=CH, CH=CH(R), C(R)=CH, OCH2, CH2O, SCH2, CH2S, CH=N, C(R)=N, N=CH, N=C(R); X 14 is S, O, N, or CH. However, when X 14 is CH, the F ring does not exist, and X 14When it is S or O, R3 does not exist; The F ring does not exist or is a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are, independently of each other, H, F, Cl, Br, I, OH, SH, CF3, substituted or unsubstituted C1-C5 alkyl, linear or branched C1-C5 or cyclic C3-C8 haloalkyl, substituted or unsubstituted linear or branched C1-C5 or cyclic C3-C8 alkoxy; Or, R1 and R2 are bonded to each other to form =O or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); Or, R2 and R4 are bonded to each other to form the F ring defined above (e.g., pyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, pyrimidine, triazole, oxadiazole, pyrazole). However, when the F ring is an aromatic ring, R1 and / or R3 do not exist; R3 and R4 are, independently of each other, H, Me, substituted or unsubstituted C1-C5 alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH(CH3)), substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclopropyl), substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 is; Or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); X14 When it is S or O, R3 does not exist; R5 is H, or a linear or branched alkyl having 1 to 5 carbon atoms (for example, methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (for example, CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (for example, (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms) (for example, CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(a substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring heterocyclic ring having 3 to 10 members) (for example, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11)(e.g., (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 (e.g., C(O)CH3), C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 substituted or unsubstituted linear or branched alkenyl, C1-C5 linear or branched or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted linear or branched or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl; Or, R6 and R5 are joined to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Or, R6 is represented by the following structural formula B or structural formula Bi:

[0124]

Chemical formula

[0125] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Or, both R 12 and R 13 are H; Or, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Or, R 12 and C3 are joined to each other to form ring A, and R 13 is R 30 ; Or, R 12 and R 13 are joined to each other to form ring B; Or, R 12 and C1 are joined to each other to form ring C, and R 13 is R 30 ; Or, C1 and C3 are joined to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Or, R 13 and C2 are joined to each other to form ring E, m is 1, and R 12 is R 30 ; Or, R 12 and R13 are bonded to each other to form ring B, and C1 and C3 are bonded to each other to form ring D; Ring A, ring C, and ring E are each independently a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring (B: piperidine, piperidin-2-one, 4-fluoropiperidin-2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7′, R7″, R7″′, and R7″″ are each independently H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0126]

Chemical formula

[0127] R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(for example, C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (for example, methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkoxy (for example, methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight-chain or branched-chain haloalkyl (for example, CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (for example, CH2-Ph), -R8-O-R8-O-R 10 (for example, (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (for example, O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (for example, (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (for example, phenyl), or a substituted or unsubstituted heteroaryl (for example, pyridine (2,3,4-pyridine)); R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl, an R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R8 is, independently of one another, [CH2] p , and p is an integer from 1 to 10 (e.g., 1, 2); R9 is [CH] q , or [C] q , and q is an integer from 2 to 10; R 10 and R 11 are, independently of one another, H, OH, COOH, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl (e.g., CH2CF3), a C1-C5 straight-chain or branched-chain alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; Or, R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); In the formula, n is an integer from 0 to 4 (e.g., 1, 2).

[0128] In some embodiments, at least one of R7′, R7″, R7″′, and R7″″′ is not H. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″′ are not H. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″′ are different from each other. In some embodiments, at least two of R7′, R7″, R7″′, and R7″″′ are not H and are different from each other.

[0129] In some embodiments, the W ring is an aromatic ring and at least one of X2, X3, and X4 is C(R). In some embodiments, the W ring is an aromatic ring and X 11 is N. In some embodiments, the W ring is an aromatic ring and X 12 is not S. In some embodiments, the W ring is an aromatic ring, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, when both the W ring and the W′ ring are aromatic rings, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H.

[0130] In some embodiments, when R1 and R2 are bonded to each other to form C═O, at least one of X2, X3, X4, and X 10 is not CH.

[0131] In various embodiments, the present invention relates to a compound represented by the following structural formula I(m), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0132]

Chem.

[0133] In the formula, The W ring can be an aromatic ring or a non-aromatic ring. When the W ring is an aromatic ring, X2, X3, and X4 are, independently of each other, CH, C(R), N (for example, C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X 15 is C; When the W ring is a non-aromatic ring, X2, X3, and X4 are, independently of each other, CH2, CH(R), C(R)2, NH, N(R), O, S, S=O, or SO2 (for example, CH2); X 15 is CH, C(R), or N (for example, CH, N); X5, X6, X7, X8, and X9 are, independently of each other, a nitrogen atom or a carbon atom. However, when any one of X5, X6, X7, X8, and X9 is nitrogen, the respective substituents of R7´, R7´´, R7, R7´´´, and R7´´´´ do not exist; X 10 is N, CH, C(R), or C=O. However, when X 10 is C=O, X 11 is N (for example, C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. However, when X 11 is N, X 10is C=O; The W' ring can be an aromatic ring or a non-aromatic ring. When the W' ring is an aromatic ring, X 12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (e.g., N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); When the W' ring is a non-aromatic ring, X 12 is CH=CH, CH=CH(R), C(R)=CH, OCH2, CH2O, SCH2, CH2S, CH=N, C(R)=N, N=CH, N=C(R); X 13 is CH2, CH(R) (e.g., CH-CH3), C(R)2, or C=O; X 14 is S, O, N, or CH. However, when X 14 is CH, the F ring does not exist, and when X 14 is S or O, R3 does not exist; The G ring either does not exist or is a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclobutane, cyclopentane, cyclohexane); The F ring either does not exist or is a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are each independently H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1-C5 alkyl, a linear or branched C1-C5 or cyclic C3-C8 haloalkyl, a substituted or unsubstituted linear or branched C1-C5, or a cyclic C3-C8 alkoxy; or, R1 and R2 are bonded to each other to form =O, or a C3-C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); or, R2 and R4 are bonded to each other to form the F ring defined above (e.g., pyrrolidine, pyrrolidin-2-one, pyrrolidin-3-ol, morpholine, pyridine, pyrimidine, triazole, oxadiazole, pyrazole). However, when the F ring is an aromatic ring, R1 and / or R3 do not exist; R3 and R4 are, independently of each other, H, Me, a C1-C5 substituted or unsubstituted alkyl (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R 10 (e.g., (CH2)2-O-CH3), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH(CH3)), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R 20 ; or, R3 and R4 are bonded to each other to form a 3- to 8-membered heterocyclic ring (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); R7´, R7´´, R7´´´, and R7´´´´ are, independently of each other, H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R11 ), CH(CF3)(NH-R 10 ), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0134] [Chemical formula]

[0135] R 30 is H, R 20, F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, C1-C5 substituted or unsubstituted linear or branched alkyl, C1-C5 linear or branched alkoxy, C1-C5 linear or branched haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R 50 is H, R 20 , F, Cl, Br, I, OH, SH, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, C1-C5 substituted or unsubstituted linear or branched alkyl, C1-C5 linear or branched alkoxy, C1-C5 linear or branched haloalkyl, -R8-R 10 (e.g., (CH2)2-O-CH3), substituted or unsubstituted aryl (e.g., phenyl), substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11)、CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight or branched alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight or branched alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight or branched haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10 (e.g., 1, 2); R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11are, independently of each other, H, OH, COOH, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl (e.g., CH2CF3), a C1-C5 straight-chain or branched-chain alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are bonded to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); wherein n is an integer from 0 to 4 (e.g., 1, 2).

[0136] In some embodiments, at least one of R7´, R7´´', R7´´´, and R7´´´´ is not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are different from each other. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H and are different from each other.

[0137] In some embodiments, the W ring is an aromatic ring and at least one of X2, X3, and X4 is C(R). In some embodiments, the W ring is an aromatic ring and X 11 is N. In some embodiments, the W ring is an aromatic ring and X 12 is not S. In some embodiments, the W ring is an aromatic ring, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12It is not S. In some embodiments, when both the W ring and the W' ring are aromatic rings, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H.

[0138] In various embodiments, the present invention relates to a compound represented by the following structural formula I(n), or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotope variant (e.g., deuterated analog), PROTAC, pharmaceutical, or any combination thereof.

[0139]

Chemical formula

[0140] Wherein, X5, X6, X7, X8, and X9 are, independently of each other, a nitrogen atom or a carbon atom. Provided that when any one of X5, X6, X8, and X9 is nitrogen, each substituent of R7', R7'', R7''', and R7'''' does not exist; X 10 is N, CH, C(R), or C=O. Provided that when X 10 is C=O, X 11 is N (e.g., C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is N or C. Provided that when X 11 is N, X 10 is C=O; X 12is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (e.g., N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); R5 is H, or a linear or branched C1-C5 alkyl (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10 , R8-(a substituted or unsubstituted C3-C8 cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(a substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring) (e.g., (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R11 ), R8-N(R 10 )(R 11 )(e.g., (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-4-cyano-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R 10 )(R 11 )(e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 (e.g., C(O)CH3), C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10)、C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl; Alternatively, R6 and R5 are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring (e.g., azepane, piperazine, 2-(piperazin-1-yl)acetamide); Alternatively, R6 is represented by the following structural formula B or structural formula Bi:

[0141]

Chemical formula

[0142] In the formula, m is 0 or 1; R 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 ; Alternatively, both R 12 and R 13 are H; Alternatively, R 12 and R 13 are, independently of each other, H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Alternatively, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; Alternatively, R 12 and R 13 are bonded to each other to form ring B; Alternatively, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; Alternatively, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; Alternatively, R 13 and C2 are bonded to each other to form ring E, m is 1, and R 12 is R 30 ; Alternatively, R 12 and R13 are bonded to each other to form ring B, and C1 and C3 are bonded to each other to form ring D; Ring A, ring C, and ring E are each independently a substituted or unsubstituted monocyclic, spiro, or fused heterocyclic ring having 3 to 8 members (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted monocyclic, spiro, or fused heterocyclic ring having 3 to 8 members (B: piperidine, piperidin-2-one, 4-fluoropiperidin 2-one, piperidine-4-carbonitrile, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); Ring D is a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutane, cyclohexane); R7′, R7″, R7″′, and R7″″ are each independently H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(heterocyclic ring having 3 to 8 members), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R10 )(R 11 ), B(OH)2, -OCH2Ph, COOH, C(O)H, -C(O)NH2, SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., isopropyl, methyl, ethyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl (e.g., CHF2), a C1-C5 straight-chain or branched-chain or C3-C8 cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl, cyclohexyl), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, tetrahydrofuran, imidazole, piperazine, piperidine, dioxazole, 2-oxopyrrolidine), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl; or, R7' and R7'' are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7'' and R7 are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); or, R7' and R7''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7''' and R7'''' are bonded to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R 20 is represented by the following structural formula:

[0143] [Chemical formula]

[0144] R 30 is H, R 20 , F, Cl, Br, I, OH, SH, alkoxy, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), CF3, CN, NO2, a substituted or unsubstituted C1-C5 straight-chain or branched-chain alkyl, a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl, R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R 10 )(e.g., C(O)CH3), NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11)、CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a C1-C5 straight-chain or branched-chain haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH), a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R8 is, independently of one another, [CH2] p and p is from 1 to 10 (e.g., 1, 2); R9 is [CH] q or [C] q and q is from 2 to 10; R 10 and R 11are, independently of each other, H, OH, COOH, a C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3, CH2CF3), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a C1-C5 substituted or unsubstituted linear or branched haloalkyl (e.g., CH2CF3), a C1-C5 linear or branched alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R; or R 10 and R 11 are joined to each other to form a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperazine, piperidine); wherein n is an integer from 0 to 4 (e.g., 1, 2).

[0145] In some embodiments, at least one of R7´, R7´´', R7´´´, and R7´´´´ is not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are different from each other. In some embodiments, at least two of R7´, R7´´', R7´´´, and R7´´´´ are not H and are different from each other.

[0146] In some embodiments, at least one of X2, X3, and X4 is C(R). In some embodiments, X 11 is N. In some embodiments, X 12 is not S. In some embodiments, at least one of X2, X3, and X4 is C(R); X 11 is N; or X 12 is not S. In some embodiments, R is not H.

[0147] In some embodiments, X2 of Structural Formulas I and / or I(a) - I(j) is N. In other embodiments, X2 is CH. In other embodiments, X2 is C(R). In other embodiments, X2 is C(CH3). In other embodiments, X2 is C(CH2CH3). In other embodiments, X2 is C-iPr. In other embodiments, X2 is C-CH2-cyclopropyl. In other embodiments, X2 is C(O-CH2-cyclopropyl). In other embodiments, X2 is C(O-CH2-methylcyclobutyl). In other embodiments, X2 is C(O-CH2-3-methyloxetane). In other embodiments, X2 is C(OCH3). In other embodiments, X2 is C(OCH2CH3). In other embodiments, X2 is C(O-(CH2)2-O-CH3). In other embodiments, X2 is C(NH-CH2-cyclopropyl). In other embodiments, X2 is C(isopropoxy). In other embodiments, X2 is C(O-CH(CH3)-CH2-O-CH3). In other embodiments, X2 is C(OCHF2). In other embodiments, X2 is C(Cl). In other embodiments, X2 is C(C(O)CH3). In other embodiments, X2 is C(OH).

[0148] In some embodiments, the W ring of Structural Formulas I(k) - I(m) is an aromatic ring or a non-aromatic ring. In some embodiments, when the W ring is an aromatic ring, X2 is CH. In other embodiments, when the W ring is an aromatic ring, X2 is C(R). In other embodiments, when the W ring is an aromatic ring, X2 is C(CH3). In other embodiments, when the W ring is an aromatic ring, X2 is C(CH2CH3). In other embodiments, when the W ring is an aromatic ring, X2 is C-iPr. In other embodiments, when the W ring is an aromatic ring, X2 is C-CH2-cyclopropyl. In other embodiments, when the W ring is an aromatic ring, X2 is C(O-CH2-cyclopropyl). In other embodiments, when the W ring is an aromatic ring, X2 is C(O-CH2-methylcyclobutyl). In other embodiments, when the W ring is an aromatic ring, X2 is C(O-CH2-3-methyloxetane). In other embodiments, when the W ring is an aromatic ring, X2 is C(OCH3). In other embodiments, when the W ring is an aromatic ring, X2 is C(OCH2CH3). In other embodiments, when the W ring is an aromatic ring, X2 is C(O-(CH2)2-O-CH3). In other embodiments, when the W ring is an aromatic ring, X2 is C(NH-CH2-cyclopropyl). In other embodiments, when the W ring is an aromatic ring, X2 is C(isopropoxy). In other embodiments, when the W ring is an aromatic ring, X2 is C(O-CH(CH3)-CH2-O-CH3). In other embodiments, when the W ring is an aromatic ring, X2 is C(OCHF2). In other embodiments, when the W ring is an aromatic ring, X2 is C(Cl). In other embodiments, when the W ring is an aromatic ring, X2 is C(C(O)CH3). In other embodiments, when the W ring is an aromatic ring, X2 is C(OH). In some embodiments, when the W ring is a non-aromatic ring, X2 is CH2. In some embodiments, when the W ring is a non-aromatic ring, X2 is CH(R). In some embodiments, when the W ring is a non-aromatic ring, X2 is C(R)2. In some embodiments, when the W ring is a non-aromatic ring, X2 is NH.In some embodiments, when the W ring is a non-aromatic ring, X2 is N(R). In some embodiments, when the W ring is a non-aromatic ring, X2 is O. In some embodiments, when the W ring is a non-aromatic ring, X2 is S. In some embodiments, when the W ring is a non-aromatic ring, X2 is S=O. In some embodiments, when the W ring is a non-aromatic ring, X2 is SO2.

[0149] In some embodiments, X3 in Structural Formulas I and / or I(a) - I(j) is N. In other embodiments, X3 is CH. In other embodiments, X3 is CH. In other embodiments, X3 is C(R). In other embodiments, X3 is C(CH3). In other embodiments, X3 is C(CH2CH3). In other embodiments, X3 is C-iPr. In other embodiments, X3 is C-CH2-cyclopropyl. In other embodiments, X3 is C(O-CH2-cyclopropyl). In other embodiments, X3 is C(O-CH2-methylcyclobutyl). In other embodiments, X3 is C(O-CH2-3-methyloxetane). In other embodiments, X3 is C(OCH3). In other embodiments, X3 is C(OCH2CH3). In other embodiments, X3 is C(O-(CH2)2-O-CH3). In other embodiments, X3 is C(NH-CH2-cyclopropyl). In other embodiments, X3 is C(isopropoxy). In other embodiments, X3 is C(O-CH(CH3)-CH2-O-CH3). In other embodiments, X3 is C(OCHF2). In other embodiments, X3 is C(Cl). In other embodiments, X3 is C(C(O)CH3). In other embodiments, X3 is C(OH).

[0150] In some embodiments, the W ring of Structural Formulas I(k) - I(m) is an aromatic ring or a non-aromatic ring. In some embodiments, when the W ring is an aromatic ring, X3 is CH. In other embodiments, when the W ring is an aromatic ring, X3 is C(R). In other embodiments, when the W ring is an aromatic ring, X3 is C(CH3). In other embodiments, when the W ring is an aromatic ring, X3 is C(CH2CH3). In other embodiments, when the W ring is an aromatic ring, X3 is C-iPr. In other embodiments, when the W ring is an aromatic ring, X3 is C-CH2-cyclopropyl. In other embodiments, when the W ring is an aromatic ring, X3 is C(O-CH2-cyclopropyl). In other embodiments, when the W ring is an aromatic ring, X3 is C(O-CH2-methylcyclobutyl). In other embodiments, when the W ring is an aromatic ring, X3 is C(O-CH2-3-methyloxetane). In other embodiments, when the W ring is an aromatic ring, X3 is C(OCH3). In other embodiments, when the W ring is an aromatic ring, X3 is C(OCH2CH3). In other embodiments, when the W ring is an aromatic ring, X3 is C(O-(CH2)2-O-CH3). In other embodiments, when the W ring is an aromatic ring, X3 is C(NH-CH2-cyclopropyl). In other embodiments, when the W ring is an aromatic ring, X3 is C(isopropoxy). In other embodiments, when the W ring is an aromatic ring, X3 is C(O-CH(CH3)-CH2-O-CH3). In other embodiments, when the W ring is an aromatic ring, X3 is C(OCHF2). In other embodiments, when the W ring is an aromatic ring, X3 is C(Cl). In other embodiments, when the W ring is an aromatic ring, X3 is C(C(O)CH3). In other embodiments, when the W ring is an aromatic ring, X3 is C(OH). In some embodiments, when the W ring is a non-aromatic ring, X3 is CH2. In some embodiments, when the W ring is a non-aromatic ring, X3 is CH(R). In some embodiments, when the W ring is a non-aromatic ring, X3 is C(R)2. In some embodiments, when the W ring is a non-aromatic ring, X3 is NH.In some embodiments, when the W ring is a non-aromatic ring, X3 is N(R). In some embodiments, when the W ring is a non-aromatic ring, X3 is O. In some embodiments, when the W ring is a non-aromatic ring, X3 is S. In some embodiments, when the W ring is a non-aromatic ring, X3 is S=O. In some embodiments, when the W ring is a non-aromatic ring, X3 is SO2.

[0151] In some embodiments, X4 of Structural Formulas I and / or I(a) - I(j) is N. In other embodiments, X4 is CH. In other embodiments, X4 is C(R). In other embodiments, X4 is C(CH3). In other embodiments, X4 is C(CH2CH3). In other embodiments, X4 is C-iPr. In other embodiments, X4 is C-CH2-cyclopropyl. In other embodiments, X4 is C(O-CH2-cyclopropyl). In other embodiments, X4 is C(O-CH2-methylcyclobutyl). In other embodiments, X4 is C(O-CH2-3-methyloxetane). In other embodiments, X4 is C(OCH3). In other embodiments, X4 is C(OCH2CH3). In other embodiments, X4 is C(O-(CH2)2-O-CH3). In other embodiments, X4 is C(NH-CH2-cyclopropyl). In other embodiments, X4 is C(isopropoxy). In other embodiments, X4 is C(O-CH(CH3)-CH2-O-CH3). In other embodiments, X4 is C(OCHF2). In other embodiments, X4 is C(Cl). In other embodiments, X4 is C(C(O)CH3). In other embodiments, X4 is C(OH).

[0152] In some embodiments, the W ring of Structural Formulas I(k) - I(m) is an aromatic ring or a non-aromatic ring. In some embodiments, when the W ring is an aromatic ring, X4 is CH. In other embodiments, when the W ring is an aromatic ring, X4 is C(R). In other embodiments, when the W ring is an aromatic ring, X4 is C(CH3). In other embodiments, when the W ring is an aromatic ring, X4 is C(CH2CH3). In other embodiments, when the W ring is an aromatic ring, X4 is C-iPr. In other embodiments, when the W ring is an aromatic ring, X4 is C-CH2-cyclopropyl. In other embodiments, when the W ring is an aromatic ring, X4 is C(O-CH2-cyclopropyl). In other embodiments, when the W ring is an aromatic ring, X4 is C(O-CH2-methylcyclobutyl). In other embodiments, when the W ring is an aromatic ring, X4 is C(O-CH2-3-methyloxetane). In other embodiments, when the W ring is an aromatic ring, X4 is C(OCH3). In other embodiments, when the W ring is an aromatic ring, X4 is C(OCH2CH3). In other embodiments, when the W ring is an aromatic ring, X4 is C(O-(CH2)2-O-CH3). In other embodiments, when the W ring is an aromatic ring, X4 is C(NH-CH2-cyclopropyl). In other embodiments, when the W ring is an aromatic ring, X4 is C(isopropoxy). In other embodiments, when the W ring is an aromatic ring, X4 is C(O-CH(CH3)-CH2-O-CH3). In other embodiments, when the W ring is an aromatic ring, X4 is C(OCHF2). In other embodiments, when the W ring is an aromatic ring, X4 is C(Cl). In other embodiments, when the W ring is an aromatic ring, X4 is C(C(O)CH3). In other embodiments, when the W ring is an aromatic ring, X4 is C(OH). In some embodiments, when the W ring is a non-aromatic ring, X4 is CH2. In some embodiments, when the W ring is a non-aromatic ring, X4 is CH(R). In some embodiments, when the W ring is a non-aromatic ring, X4 is C(R)2. In some embodiments, when the W ring is a non-aromatic ring, X4 is NH.In some embodiments, when the W ring is a non-aromatic ring, X4 is N(R). In some embodiments, when the W ring is a non-aromatic ring, X4 is O. In some embodiments, when the W ring is a non-aromatic ring, X4 is S. In some embodiments, when the W ring is a non-aromatic ring, X4 is S=O. In some embodiments, when the W ring is a non-aromatic ring, X4 is SO2.

[0153] In some embodiments, X5 of Structural Formulas I and / or I(a) - I(n) is a nitrogen atom. In other embodiments, X5 is a carbon atom. In some embodiments, when X5 is nitrogen, R7´ does not exist.

[0154] In some embodiments, X6 of Structural Formulas I and / or I(a) - I(n) is a nitrogen atom. In other embodiments, X6 is a carbon atom. In some embodiments, when X6 is nitrogen, R7´´ does not exist.

[0155] In some embodiments, X7 of Structural Formulas I and / or I(a) - I(k) and / or I(n) is a nitrogen atom. In other embodiments, X7 is a carbon atom. In some embodiments, when X7 is nitrogen, R7 does not exist.

[0156] In some embodiments, X8 of Structural Formulas I and / or I(a) - I(n) is a nitrogen atom. In other embodiments, X8 is a carbon atom. In some embodiments, when X8 is nitrogen, R7´´´ does not exist.

[0157] In some embodiments, X9 of Structural Formulas I and / or I(a) - I(n) is a nitrogen atom. In other embodiments, X9 is a carbon atom. In some embodiments, when X9 is nitrogen, R7´´´´ does not exist.

[0158] In some embodiments, X of Structural Formulas I and / or I(a) - I(n) 10 is a nitrogen atom. In other embodiments, X 10is carbon. In other embodiments, X 10 is N. In other embodiments, X 10 is CH. In other embodiments, X 10 is C(R), where R is as defined below. In other embodiments, X 10 is C(R), where R is alkyl. In other embodiments, X 10 is C(R), where R is methyl, substituted methyl, CH2-OH, ethyl, substituted ethyl, CH2-CH2-OH, NH(R 10 ), NH-CH2-cyclopropyl, COOH, cycloalkyl such as cyclopropyl, alkoxy such as isopropoxy. Each corresponds to a separate embodiment of the present invention. In other embodiments, X 10 is C(R), where R is substituted alkyl. In other embodiments, X 10 is C(R), where R is CH2-OH. In other embodiments, X 10 is C(R), where R is CH2-CH2-OH. In other embodiments, X 10 is C(R), where R is cycloalkyl. In other embodiments, X 10 is C(R), where R is cyclopropyl. In other embodiments, X 10 is C(R), where R is not methyl. In other embodiments, X 10 is C(R), where R is alkoxy. In other embodiments, X 10 is C(R), where R is isopropoxy. In other embodiments, X 10 is C(CH2-OH). In other embodiments, X 10 is C(CH2-CH2-OH). In other embodiments, X 10 is C(R), where R is N(H)R 10 and R 10 is substituted alkyl. In other embodiments, X 10 is C(NH-CH2-cyclopropyl). In other embodiments, X 10 is C(COOH). In other embodiments, X 10 is C(CH3). In other embodiments, X10 is C (cyclopropyl). In other embodiments, X 10 is C (isopropoxy). In other embodiments, X 10 is C=O. In other embodiments, X 10 When X is C=O, X 11 is N.

[0159] In some embodiments, X in Structural Formulas I and / or I(a) to I(n) 11 is a nitrogen atom. In other embodiments, X 11 is a carbon atom. In other embodiments, X 11 is N. In other embodiments, X 11 is C. In other embodiments, X 11 When X is N, X 10 is C=O. In other embodiments, X 10 When X is C=O, X 11 is N. In some embodiments, X in Structural Formula I(j) 11 is CH. In some embodiments, X in Structural Formula I(j) 11 is C(R).

[0160] In some embodiments, X in Structural Formulas I and / or I(a) to I(j) 12 is S. In other embodiments, X 12 is not S. In other embodiments, X 12 is SO2. In other embodiments, X 12 is O. In other embodiments, X 12 is NH. In other embodiments, X 12 is N(R). In other embodiments, X 12 is N-CH2-COOH. In other embodiments, X 12 is N-CH2-CH2-OH. In other embodiments, X 12 is N-CH3. In other embodiments, X 12 is N-OH. In other embodiments, X 12 is CH=CH. In other embodiments, X 12is CH=CH(R). In other embodiments, X 12 is C(R)=CH. In other embodiments, X 12 is N=CH. In other embodiments, X 12 is N=C(R). In other embodiments, X 12 is CH=N. In other embodiments, X 12 is C(R)=N. In other embodiments, X 12 is N-CH2CH3. In other embodiments, X 12 is N-iPr. In other embodiments, X 12 is N-cyclopropyl. In other embodiments, X 12 is N-CH2-cyclopropyl.

[0161] In some embodiments, the W ring' of structural formulas I(k) to I(m) is aromatic or non-aromatic. In some embodiments, when the W ring' is aromatic, X 12 is S. In other embodiments, when the W ring' is aromatic, X 12 is not S. In other embodiments, when the W ring' is aromatic, X 12 is SO2. In other embodiments, when the W ring' is aromatic, X 12 is O. In other embodiments, when the W ring' is aromatic, X 12 is NH. In other embodiments, when the W ring' is aromatic, X 12 is N(R). In other embodiments, when the W ring' is aromatic, X 12 is N-CH2-COOH. In other embodiments, when the W ring' is aromatic, X 12 is N-CH2-CH2-OH. In other embodiments, when the W ring' is aromatic, X 12 is N-CH3. In other embodiments, when the W ring' is aromatic, X 12 is N-OH. In other embodiments, when the W ring' is aromatic, X 12 is CH=CH. In other embodiments, when the W ring' is aromatic, X 12is CH=CH(R). In other embodiments, when W ring ′ is aromatic, X 12 is C(R)=CH. In other embodiments, when W ring ′ is aromatic, X 12 is N=CH. In other embodiments, when W ring ′ is aromatic, X 12 is N=C(R). In other embodiments, when W ring ′ is aromatic, X 12 is CH=N. In other embodiments, when W ring ′ is aromatic, X 12 is C(R)=N. In other embodiments, when W ring ′ is aromatic, X 12 is N-CH2CH3. In other embodiments, when W ring ′ is aromatic, X 12 is N-iPr. In other embodiments, when W ring ′ is aromatic, X 12 is N-cyclopropyl. In other embodiments, when W ring ′ is aromatic, X 12 is N-CH2-cyclopropyl. In other embodiments, when W ring ′ is non-aromatic, X 12 is CH=CH. In other embodiments, when W ring ′ is non-aromatic, X 12 is CH=CH(R). In other embodiments, when W ring ′ is non-aromatic, X 12 is C(R)=CH. In other embodiments, when W ring ′ is non-aromatic, X 12 is OCH2. In other embodiments, when W ring ′ is non-aromatic, X 12 is CH2O. In other embodiments, when W ring ′ is non-aromatic, X 12 is SCH2. In other embodiments, when W ring ′ is non-aromatic, X 12 is CH2S. In other embodiments, when W ring ′ is non-aromatic, X 12 is CH=N. In other embodiments, when W ring ′ is non-aromatic, X 12 is C(R)=N. In other embodiments, when W ring ′ is non-aromatic, X 12 is N=CH. In other embodiments, when W ring ′ is non-aromatic, X 12 is N=C(R).

[0162] In some embodiments, X in Structural Formulas I(b), I(c), I(f), I(h), and / or I(m) 13 is CH2. In other embodiments, X 13 is CH(R). In other embodiments, X 13 is CH-CH3. In other embodiments, X 13 is C(R)2. In other embodiments, X 13 is C=O.

[0163] In some embodiments, X in Structural Formulas I(g), I(h), I(l), and / or I(m) 14 is S. In other embodiments, X 14 is O. In other embodiments, X 14 is N. In other embodiments, X 14 is CH. In other embodiments, when X 14 is CH, the F ring is absent. In other embodiments, when X 14 is S, R3 is absent. In other embodiments, when X 14 is O, R3 is absent.

[0164] In some embodiments, at least one of X2, X3, X4, X5, X6, X7, X8, and X9 in Structural Formulas I, I(a) - I(c), and / or I(i) - I(k) is a nitrogen atom. In some embodiments, at least one of X2, X3, X4, X5, X6, X8, and X9 in Structural Formulas I, and / or I(a) - I(m) is a nitrogen atom. In some embodiments, at least one of X2, X3, X4, X5, X6, X7, X8, and X9 in Structural Formula I(d) is a nitrogen atom. In some embodiments, at least one of X2, X3, X4, X5, X6, X7, X8, X9, and X 10 is a nitrogen atom. In some embodiments, when any one of X5, X6, X7, X8, and X9 is nitrogen, the R7´, R7´´, R7, R7´´´, R7´´´´ substituents are absent.

[0165] In some embodiments, when the W ring is an aromatic ring, X in Structural Formulas I(k) to I(m) 15 is C. In some embodiments, when the W ring is a non-aromatic ring, X 15 is CH, C(R), or N. Each corresponds to a separate embodiment of the present invention. In some embodiments, when the W ring is a non-aromatic ring, X 15 is CH. In some embodiments, when the W ring is a non-aromatic ring, X 15 is C(R). In some embodiments, when the W ring is a non-aromatic ring, X 15 is N.

[0166] In some embodiments, R5 in Structural Formulas I, I(a), I(d), I(e), I(g), and / or I(i) to I(n) is H. In other embodiments, R5 is a straight-chain or branched-chain C1-C5 alkyl. In other embodiments, R5 is methyl. In other embodiments, R5 is methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, neopentyl. Each corresponds to a separate embodiment of the present invention.

[0167] In some embodiments, R5 and R6 in Structural Formulas I, I(a), I(d), I(e), I(g), and / or I(i) to I(n) are bonded to each other to form a substituted or unsubstituted 5- to 8-membered heterocyclic ring. In some embodiments, R5 and R6 are bonded to each other to form a substituted 5- to 8-membered heterocyclic ring. In some embodiments, R5 and R6 are bonded to each other to form an unsubstituted 5- to 8-membered heterocyclic ring. In some embodiments, the heterocyclic ring is azepane, piperazine, or 2-(piperazin-1-yl)acetamide. Each corresponds to a separate embodiment of the present invention. In some embodiments, the heterocyclic ring is F, Cl, Br, I, CF3, R 20 , a straight-chain or branched-chain C1-C5 alkyl, a straight-chain or branched-chain C1-C5 haloalkyl, OH, alkoxy, R8-OH (e.g., CH2-OH), OMe, amide, C(O)N(R)2, C(O)N(R 10)(R 11 )、R8-C(O)N(R 10 )(R 11 )、C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 )、N(R 10 )(R 11 )、N(CH3)2, NH2, CF3, aryl, phenyl, heteroaryl, C3-C8 substituted or unsubstituted cycloalkyl, cyclobutanol, substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., saturated, unsaturated, or aromatic monocyclic, fused-ring, or spiro-ring of pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and is substituted by at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention.

[0168] In some embodiments, R6 of structural formulas I, I(a), I(d), I(e), I(g), I(i), I(j)~I(l), and / or I(n) is H. In other embodiments, R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 , CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2, R8-S-R 10 , (CH2)3-S-(CH2)2CH3, R8-NHC(O)-R 10 , -O-R8-R 10, R8-(C3-C8 substituted or unsubstituted cycloalkyl), CH2-cyclopropyl, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol, R8-(substituted or unsubstituted, monocyclic, fused ring, or spiro ring 3- to 10-membered heterocyclic ring), (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, CH2-azaspiroheptane, CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8-CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), (CH2)2-NH2, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-piperidin-2-one, (CH2)3-4-cyano-piperidine, (CH2)3-4-trifluoromethyl-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3), R8-C(O)N(R 10 )(R 11 ), (CH2)2-C(O)-piperidine, R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11)、COOH, -C(O)Ph, C(O)O-R 10 、R8-C(O)-R 10 、C(O)H, C(O)-R 10 (e.g., C(O)CH3), C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3, CH(CH3)C(O)N(CH3)2, C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, C1-C5 straight-chain or branched-chain or C3-C8 cyclic haloalkyl, C1-C5 substituted or unsubstituted straight-chain or branched-chain or C3-C8 cyclic alkoxymethoxy (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), O-(CH2)2-O-CH3, C1-C5 straight-chain or branched-chain thioalkoxy, C1-C5 straight-chain or branched-chain haloalkoxy, C1-C5 straight-chain or branched-chain alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, cyclopropyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol, R8-(C3-C8 substituted or unsubstituted cycloalkyl), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryl, substituted or unsubstituted R8-aryl (e.g., benzyl), or substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention.In some embodiments, R6 is F, Cl, Br, I, a straight-chain or branched-chain C1-C5 alkyl, OH, alkoxy, OMe, amide, C(O)N(R)2, C(O)-alkyl, C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), N(CH3)2, NH2, CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted C3-C8 cycloalkyl, cyclobutanol, a substituted or unsubstituted 3- to 8-membered heterocyclic ring, pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole, halophenyl, (benzyloxy)phenyl, CN, and NO2, and may be further substituted by at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is H. In some embodiments, R6 is -R8-O-R 10 . In some embodiments, R6 is CH2-O-CH3. In some embodiments, R6 is R8-S-R 10 . In some embodiments, R6 is (CH2)3-S-(CH2)2CH3. In some embodiments, R6 is R8-NHC(O)-R 10 . In some embodiments, R6 is (CH2)3-NHC(O)-R 10 . In some embodiments, R6 is (CH2)-NHC(O)-R 10is. In some embodiments, R6 is R8-(substituted or unsubstituted C3-C8 cycloalkyl). Examples of R8-(substituted or unsubstituted C3-C8 cycloalkyl) include, but are not limited to, CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, and CH2-cyclohexanol. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is R8-(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3- to 8-membered heterocyclic ring). In some embodiments, R6 is R8-(substituted or unsubstituted saturated monocyclic 3- to 8-membered heterocyclic ring). In some embodiments, R6 is R8-(substituted or unsubstituted unsaturated monocyclic 3- to 8-membered heterocyclic ring). In some embodiments, R6 is R8-(substituted or unsubstituted aromatic 3- to 8-membered monocyclic ring). In some embodiments, R6 is R8-(substituted or unsubstituted saturated fused-ring 3- to 8-membered heterocyclic ring). In some embodiments, R6 is R8-( is a 3- to 8-membered heterocyclic ring of a substituted or unsubstituted unsaturated fused ring). In some embodiments, R6 is R8-(a 3- to 8-membered heterocyclic ring of a substituted or unsubstituted aromatic fused ring). In some embodiments, R6 is R8-(a 3- to 8-membered heterocyclic ring of a substituted or unsubstituted fused ring). Examples of R8-(a substituted or unsubstituted saturated, unsaturated, or aromatic monocyclic, fused ring, or spiro ring 3- to 8-membered heterocyclic ring) include, but are not limited to, (CH2)3-piperidine, (CH2)3-4-fluoro-piperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2)3-diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-tetrahydrofuran, CH2-oxa-azaspirodecan, CH2-azaspiroheptane, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methyl-azetidine, and CH2-azaspiroheptane. In some embodiments, R6 is NH2. In some embodiments, R6 is NHR. In some embodiments, R6 is N(R)2. In some embodiments, R6 is NH(R 10 ). In some embodiments, R6 is N(R 10 )(R 11 ). In some embodiments, R6 is R8-N(R 10 )(R 11 ). In some embodiments, R8-N(R 10 )(R 11 ) examples include, but are not limited to, (CH2)3-N(CH2CH3)2, (CH2)3-N(CH(CH3)2)2, (CH2)3-piperidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, and (CH2)3-N(CH2CH3)(CH2CF3). In some embodiments, R6 is R8-C(O)N(R10 )(R 11)), for example, (CH2)2-C(O)-piperidine, etc. In some embodiments, R6 is a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl. Examples of C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl include CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), CH(CH3)C(O)N(CH3)2, benzyl, methyl, ethyl, and CH2-OCH2-CH2-O-CH3. In some embodiments, R6 is methyl. In some embodiments, R6 is a C3-C8 substituted or unsubstituted cycloalkyl. In some embodiments, examples of C3-C8 substituted or unsubstituted cycloalkyl include cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, cyclopropyl, aminomethyl-cyclobutyl, methoxycyclobutyl, and 2,3-dihydro-1H-indene. In some embodiments, R6 is R8-(C3-C8 substituted or unsubstituted cycloalkyl). In some embodiments, R6 is a substituted or unsubstituted saturated, unsaturated, or aromatic monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring. In some embodiments, the substituted or unsubstituted saturated, unsaturated, or aromatic monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring is piperidine, 1-methyl-piperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3.3]heptane, imidazole, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, azepan-2-one, or azabicyclohexane. Each corresponds to a separate embodiment of the present invention. In some embodiments, in some embodiments, R6 is piperidine.In some embodiments, R6 is 1-methyl-piperidine. In some embodiments, R6 is tetrahydropyran. R6 is a substituted or unsubstituted R8-aryl, such as benzyl and the like. In some embodiments, R6 is F, Cl, Br, I, CF3, R. 20 , a straight-chain or branched-chain alkyl having 1 to 5 carbon atoms, a straight-chain or branched-chain haloalkyl having 1 to 5 carbon atoms, OH, alkoxy, R8-OH (e.g., CH2-OH), OMe, amide, C(O)N(R)2, C(O)N(R 10 )(R 11 ), R8-C(O)N(R 10 )(R 11 ), C(O)-pyrrolidine, C(O)-piperidine, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), N(CH3)2, NH2, CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms, cyclobutanol, a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., a saturated, unsaturated, or aromatic monocyclic, fused-ring, or spiro-ring pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2 and may be further substituted by at least one substituent selected from. Each corresponds to a separate embodiment of the present invention.

[0169] In some embodiments, R6 and R5 of Structural Formulas I, I(a), I(d), I(e), I(g), I(i), I(j)-I(l), and / or I(n) are joined to each other to form a substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 5- to 8-membered heterocyclic ring. In some embodiments, the substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 5- to 8-membered heterocyclic ring is azepane, piperazine, or 2-(piperazin-1-yl)acetamide. Each corresponds to a separate embodiment of the present invention. In some embodiments, the ring is F, Cl, Br, I, C1-C5 straight-chain or branched-chain alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2 and may be further substituted by at least one substituent selected from. Each corresponds to a separate embodiment of the present invention.

[0170] In some embodiments, R6 of Structural Formulas I, I(a), I(d), I(e), I(g), I(i), I(j)-I(l), and / or I(n) is represented by Structural Formula B below.

[0171]

Chemical Formula

[0172] wherein, m is 0 or 1; and, R 12 is R 20or a C(O)-alkyl of C1-C5, R 13 is R 30 ; or, R 12 and R 13 are both H; or, R 12 and R 13 are independently of each other H, or a substituted or unsubstituted alkyl of C1-C5 (for example, ethyl, trifluoroethyl); or, R 12 and C3 are bonded to each other to form an A ring, and R 13 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring; or, R 12 and C1 are bonded to each other to form a C ring, and R 13 is R 30 ; or, C1 and C3 are bonded to each other to form a D ring, and R 12 and R 13 are independently of each other R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring; The A ring, C ring, and E ring are independently of each other a substituted or unsubstituted monocyclic, spiro, or fused ring heterocyclic ring of 3 to 8 members; The B ring is a substituted or unsubstituted monocyclic, spiro, or fused ring heterocyclic ring of 3 to 8 members; and, The D ring is a substituted or unsubstituted cycloalkyl of C3-C8.

[0173] In some embodiments, Structural Formula B is represented by Structural Formula Bi.

[0174] In some embodiments, R6 of Structural Formulas I, I(a), I(d), I(e), I(g), I(i), I(j) - I(l), and / or I(n) is represented by Structural Formula Bi below.

[0175]

Chemical Formula

[0176] In the formula, m is 0 or 1; and, R 12 is R 20 or C1 - C5 C(O)-alkyl, R 13 is R 30 ; or, R 12 and R 13 are both H; or, R 12 and R 13 are independently of each other H, or C1 - C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); or, R 12 and C3 are bonded to each other to form ring A, and R 13 is R 30 ; or, R 12 and R 13 are bonded to each other to form ring B; or, R 12 and C1 are bonded to each other to form ring C, and R 13 is R 30 ; or, C1 and C3 are bonded to each other to form ring D, and R 12 and R 13 are independently of each other R 30 ; or, R 13 and C2 are bonded to each other to form ring E, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form ring B, and C1 and C3 are bonded to each other to form ring D; Ring A, Ring C, and Ring E are each independently a substituted or unsubstituted monocyclic, spirocyclic, or fused-ring heterocyclic ring having 3 to 8 members; Ring B is a substituted or unsubstituted monocyclic, spirocyclic, or fused-ring heterocyclic ring having 3 to 8 members; and, Ring D is a C3-C8 substituted or unsubstituted cycloalkyl.

[0177] In some embodiments, R in Structural Formulas B and / or Bi 12 is H. In some embodiments, R 12 is R 20 . In other embodiments, R 12 is R 30 . In some embodiments, R 12 is C1-C5 C(O)-alkyl. In some embodiments, R 12 is a C1-C5 substituted or unsubstituted alkyl. In some embodiments, R 12 is an unsubstituted C1-C5 alkyl. In some embodiments, the alkyl is ethyl. In some embodiments, R 12 is a substituted C1-C5 alkyl. In some embodiments, the alkyl is trifluoroethyl.

[0178] In some embodiments, R in Structural Formulas B and / or Bi 13 is H. In other embodiments, R 13 is R 30 . In some embodiments, R 13 is a C1-C5 substituted or unsubstituted alkyl. In some embodiments, R 13 is an unsubstituted C1-C5 alkyl. In some embodiments, the alkyl is ethyl. In some embodiments, R 13 is a substituted C1-C5 alkyl. In some embodiments, the alkyl is trifluoroethyl.

[0179] In some embodiments, R6 of Structural Formulas I, I(a), I(d), I(e), I(g), I(i), I(j) - I(l), and / or I(n) is represented by Structural Formula B. In some embodiments, R of Structural Formula B 12 is R 20 , or C1 - C5 C(O)-alkyl, and R 13 is R 30 . In some embodiments, R 12 and R 13 of Structural Formula B are both H. In some embodiments, R 12 and R 13 of Structural Formula B are independently of each other H, or C1 - C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl). In some embodiments, R 12 and R 13 of Structural Formula B are independently of each other H or trifluoroethyl. In some embodiments, R 12 and C3 of Structural Formula B are bonded to each other to form Ring A, and R 13 is R 30 . In some embodiments, R 12 and R 13 of Structural Formula B are bonded to each other to form Ring B. In some embodiments, R 12 and C1 of Structural Formula B are bonded to each other to form Ring C, and R 13 is R 30 . In some embodiments, C1 and C3 of Structural Formula B are bonded to each other to form Ring D, and R 12 and R 13 of Structural Formula B are independently of each other R 30 . In some embodiments, R 13 and C2 of Structural Formula B are bonded to each other to form Ring E, m is 1, and R 12 of Structural Formula B is R 30 . In some embodiments, R 12 and R 13 of Structural Formula B are bonded to each other to form Ring B, and C1 and C3 of Structural Formula B are bonded to each other to form Ring D.

[0180] In some embodiments, R6 of Structural Formulas I, I(a), I(d), I(e), I(g), I(i), I(j)-I(l), and / or I(n) is represented by Structural Formula Bi. In some embodiments, R of Structural Formula Bi 12 is R 20 , or C1-C5 C(O)-alkyl, and R 13 is R 30 . In some embodiments, R 12 and R 13 of Structural Formula Bi are both H. In some embodiments, R 12 and R 13 of Structural Formula Bi are independently of each other H, or C1-C5 substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl). In some embodiments, R 12 and R 13 of Structural Formula Bi are independently of each other H or trifluoroethyl. In some embodiments, R 12 and C3 of Structural Formula Bi are bonded to each other to form Ring A, and R 13 is R 30 . In some embodiments, R 12 and R 13 of Structural Formula Bi are bonded to each other to form Ring B. In some embodiments, R 12 and C1 of Structural Formula Bi are bonded to each other to form Ring C, and R 13 is R 30 . In some embodiments, C1 and C3 of Structural Formula Bi are bonded to each other to form Ring D, and R 12 and R 13 of Structural Formula Bi are independently of each other R 30 . In some embodiments, R 13 and C2 of Structural Formula Bi are bonded to each other to form Ring E, m is 1, and R 12 of Structural Formula Bi is R 30 . In some embodiments, R 12 and R 13 of Structural Formula Bi are bonded to each other to form Ring B, and C1 and C3 of Structural Formula Bi are bonded to each other to form Ring D.

[0181] In some embodiments, R6 of Structural Formulas I, I(a), I(d), I(e), I(g), I(i), I(j) - I(l), and / or I(n) is represented by Structural Formulas Bi and / or B, R of Structural Formulas Bi and / or B 12 is R 20 , or C1 - C5 C(O)-alkyl, and R of Structural Formulas Bi and / or B 13 is R 30 ; or, R 12 and R 13 are both H, or R 12 and R 13 are independently of each other H or trifluoroethyl; or, R 12 and C3 are bonded to each other to form an A ring, and R 13 is R 30 ; or, R 12 and R 13 are bonded to each other to form a substituted or unsubstituted pyrrolidine ring, piperazine, thiomorpholine 1,1 - dioxide, 2 - oxa - 6 - azaspiro[3.3]heptane, pyrazole, imidazole, 2,5 - diazabicyclo[2.2.1]heptane, or diazabicyclo[2.2.1]heptane; or, R 12 and C1 are bonded to each other to form a C ring, and R 13 is R 30 ; or, C1 and C3 are bonded to each other to form a D ring, and R 12 and R 13 are independently of each other R 30 ; or, R 13 and C2 are bonded to each other to form an E ring, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form a B ring, and C1 and C3 are bonded to each other to form a D ring.

[0182] In some embodiments, R6 of Structural Formulas I, I(a), I(d), I(e), I(g), I(i), I(j)-I(l), and / or I(n) is represented by Structural Formulas Bi and / or B, R of Structural Formulas Bi and / or B 12 is R 20 , or C1-C5 C(O)-alkyl, and R of Structural Formulas Bi and / or B 13 is R 30 ; or, R 12 and C3 are bonded to each other to form Ring A, and R 13 is R 30 ; or, R 12 and R 13 are bonded to each other to form a substituted or unsubstituted pyrrolidine ring, piperazine, thiomorpholine 1,1-dioxide, 2-oxa-6-azaspiro[3.3]heptane, pyrazole, imidazole, 2,5-diazabicyclo[2.2.1]heptane, or diazabicyclo[2.2.1]heptane; or, R 12 and C1 are bonded to each other to form Ring C, and R 13 is R 30 ; or, C1 and C3 are bonded to each other to form Ring D, and R 12 and R 13 are independently of each other R 30 ; or, R 13 and C2 are bonded to each other to form Ring E, m is 1, and R 12 is R 30 ; or, R 12 and R 13 are bonded to each other to form Ring B, and C1 and C3 are bonded to each other to form Ring D.

[0183] In some embodiments, ring A of Structural Formula Bi is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring. In some embodiments, ring A is an unsubstituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, ring A is an unsubstituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, ring A is an unsubstituted fused 3- to 8-membered heterocyclic ring. In some embodiments, ring A is a substituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, ring A is a substituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, ring A is a substituted fused 3- to 8-membered heterocyclic ring. In some embodiments, ring A is pyrrolidine, methylpyrrolidine, ethylpyrrolidine, 2-oxopyrrolidine, piperidine, methylpiperidine, methyl-2-oxopyrrolidine, pyran-azetidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, or 2-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, ring A is pyrrolidine, methylpyrrolidine, or ethylpyrrolidine. Each corresponds to a separate embodiment of the present invention.

[0184] In some embodiments, the B ring of Structural Formula Bi is a substituted or unsubstituted monocyclic, spirocyclic or fused ring heterocyclic ring with 3 to 8 members. In some embodiments, the B ring is an unsubstituted monocyclic heterocyclic ring with 3 to 8 members. In some embodiments, the B ring is an unsubstituted spirocyclic heterocyclic ring with 3 to 8 members. In some embodiments, the B ring is an unsubstituted fused ring heterocyclic ring with 3 to 8 members. In some embodiments, the B ring is a substituted monocyclic heterocyclic ring with 3 to 8 members. In some embodiments, the B ring is a substituted spirocyclic heterocyclic ring with 3 to 8 members. In some embodiments, the B ring is a substituted fused ring heterocyclic ring with 3 to 8 members. In some embodiments, the B ring is pyrrolidine, methylpyrrolidine, ethylpyrrolidine, 2-oxopyrrolidine, hydroxymethyl-pyrrolidine piperidine, methylpiperidine, fluoropiperidine, difluoropiperidine, piperazine, methyl-piperazine, dimethyl-pyrazole, methyl-2-oxopyrrolidine, pyran-, azetidine, methyl-azetidine, imidazole, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, or 2-azaspiro[3.3]heptane, diazabicyclo[2.2.1]heptane, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, thiomorpholine, or, 1,1-dioxide-2-oxa-6-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, the B ring is piperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine, methyl-piperazine, dimethyl-pyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, 1,1-dioxide-2-oxa-6-azaspiro[3.3]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, or, 6-fluoro-3-azabicyclo[3.1.1]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, the B ring is 4-fluoropiperidine.

[0185] In some embodiments, Ring C of Structural Formula Bi is a substituted or unsubstituted monocyclic, spiro, or fused 3- to 8-membered heterocyclic ring. In some embodiments, Ring C is an unsubstituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, Ring C is an unsubstituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, Ring C is an unsubstituted fused 3- to 8-membered heterocyclic ring. In some embodiments, Ring C is a substituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, Ring C is a substituted spiro 3- to 8-membered heterocyclic ring. In some embodiments, Ring C is a substituted fused 3- to 8-membered heterocyclic ring. In some embodiments, Ring C is pyrrolidine, methylpyrrolidine, ethylpyrrolidine, 2-oxopyrrolidine, piperidine, methylpiperidine, methyl-2-oxopyrrolidine, pyran-azetidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, or 2-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, Ring C is piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, or 2-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention.

[0186] In some embodiments, Ring D of Structural Formula Bi is a C3-C8 substituted or unsubstituted cycloalkyl. In some embodiments, Ring D is a substituted C3-C8 cycloalkyl. In some embodiments, Ring D is an unsubstituted C3-C8 cycloalkyl. In some embodiments, Ring D is cyclopropane, cyclobutene, cyclopentane, cyclohexane, or cycloheptane. Each corresponds to a separate embodiment of the present invention.

[0187] In some embodiments, Ring E of Structural Formula Bi is a substituted or unsubstituted, monocyclic, spirocyclic, or fused 3- to 8-membered heterocyclic ring. In some embodiments, Ring E is an unsubstituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, Ring E is an unsubstituted spirocyclic 3- to 8-membered heterocyclic ring. In some embodiments, Ring E is an unsubstituted fused 3- to 8-membered heterocyclic ring. In some embodiments, Ring E is a substituted monocyclic 3- to 8-membered heterocyclic ring. In some embodiments, Ring E is a substituted spirocyclic 3- to 8-membered heterocyclic ring. In some embodiments, Ring E is a substituted fused 3- to 8-membered heterocyclic ring. In some embodiments, Ring E is pyrrolidine, methylpyrrolidine, ethylpyrrolidine, 2-oxopyrrolidine, piperidine, methylpiperidine, methyl-2-oxopyrrolidine, pyran-azetidine, methyl-azetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, or 2-azaspiro[3.3]heptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, Ring E is pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, or methylpiperidine. Each corresponds to a separate embodiment of the present invention.

[0188] In some embodiments, R6 of Structural Formulas I, I(a), I(d), I(e), I(g), I(i), I(j)~I(l), and / or I(n) is F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R 10 (e.g., CH2-O-CH3), R8-S-R 10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R 10 , -O-R8-R 10, R8- (e.g., CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), (CH2)3-pyran, CH2-tetrahydrofuran, CH2-dioxane, CH2-methyl-THF, CH2-oxa-azaspirodecan, (CH2)3-dimethylpyrazole, CH2-methyl-azetidine, CH2-azaspiroheptane, CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8-CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 (e.g., C(O)CH3), C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a straight-chain or branched-chain, substituted or unsubstituted alkyl having 1 to 5 carbon atoms (e.g., CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), benzyl, methyl, ethyl, CH2-OCH2-CH2-O-CH3), a straight-chain or branched-chain, substituted or unsubstituted alkenyl having 1 to 5 carbon atoms, a straight-chain or branched-chain haloalkyl having 1 to 5 carbon atoms or a cyclic haloalkyl having 3 to 8 carbon atoms, a straight-chain or branched-chain, substituted or unsubstituted alkoxy having 1 to 5 carbon atoms or a cyclic alkoxy having 3 to 8 carbon atoms (e.g., methoxy, O-(CH2)2-O-CH3, and optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), a straight-chain or branched-chain thioalkoxy having 1 to 5 carbon atoms, a straight-chain or branched-chain haloalkoxy having 1 to 5 carbon atoms, a straight-chain or branched-chain alkoxyalkyl having 1 to 5 carbon atoms, a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (e.g., methoxycyclopropyl, methylcyclobutyl, cyclopropyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), a substituted or unsubstituted heterocyclic ring having 3 to 8 members (e.g., trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, 1-methylazepan-2-one, 3-azabicyclo[3.1.0]hexane), a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is F, Cl, Br, I, a straight-chain or branched-chain alkyl having 1 to 5 carbon atoms, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-alkyl, C(O)-pyrrolidine, C(O)-piperidine, N(R)2 (e.g., N(CH3)2, NH2), NH(R 10 ), N(R 10 )(R 11)、CF3, aryl, phenyl, heteroaryl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and may be further substituted with at least one substituent selected from the group consisting of. Each corresponds to a separate embodiment of the present invention.

[0189] In some embodiments, R6 of structural formulas I, I(a), I(d), I(e), I(g), I(i), I(j)-I(l), and / or I(n) is -R8-O-R 10 is. In some embodiments, -R8-O-R 10 is CH2-O-CH3. In some embodiments, R6 is R8-S-R 10 is. In some embodiments, R8-S-R 10 is (CH2)3-S-(CH2)2CH3. In some embodiments, R6 is R8-NHC(O)-R 10It is. In some embodiments, R6 is R8-(substituted or unsubstituted C3-C8 cycloalkyl). In some embodiments, R8-(substituted or unsubstituted C3-C8 cycloalkyl) is CH2-cyclobutanol, CH2-difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylamino-cyclohexyl, (CH2)2-cyclopentanol, or CH2-cyclohexanol. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is R8-(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused, or spiro 3- to 10-membered heterocyclic ring). In some embodiments, R6 is (CH2)3-piperidine. In some embodiments, R6 is (CH2)3-NH2. In some embodiments, R6 is (CH2)3-NH2. In some embodiments, R6 is (CH2)3-4-fluoropiperidine. In some embodiments, R6 is (CH2)3-pyran, CH2-tetrahydrofuran, CH2-dioxane, CH2-methyl-THF, CH2-oxa-azaspirodecane, (CH2)3-dimethylpyrazole, CH2-methyl-azetidine, or CH2-azaspiroheptane. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is a straight-chain or branched-chain substituted or unsubstituted C1-C5 alkyl. In some embodiments, R6 is a straight-chain or branched-chain substituted C1-C5 alkyl. In some embodiments, the substituted alkyl is CH(CH3)CH2OCH3, CH(CH3)CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH3), CH2CH(N(CH3)2)(CH2CH3), CH2-OCH2-CH2-O-CH3, or benzyl. Each corresponds to a separate embodiment of the present invention.In some embodiments, R6 is a straight-chain or branched-chain unsubstituted C1-C5 alkyl. In some embodiments, the unsubstituted alkyl is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, or neopentyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is a substituted or unsubstituted C3-C8 cycloalkyl. In some embodiments, R6 is a substituted C3-C8 cycloalkyl. In some embodiments, the substituted cycloalkyl is methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, or 2,3-dihydro-1H-indenol. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is an unsubstituted C3-C8 cycloalkyl. In some embodiments, the unsubstituted cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is a substituted or unsubstituted 3- to 8-membered heterocyclic ring. In some embodiments, the substituted heterocyclic ring is piperidine, 1-methyl-piperidine, tetrahydropyran, trifluoromethyl-oxetane, hydroxy-tetrahydrofuran, 1-methylazepan-2-one, or 3-azabicyclo[3.1.0]hexane. Each corresponds to a separate embodiment of the present invention. In some embodiments, R6 is piperidine. In some embodiments, R6 is 1-methyl-piperidine. In some embodiments, R6 is tetrahydropyran.

[0190] In some embodiments, R7 of structural formulas I, I(a) to I(c), I(i), I(j), I(k), and / or I(n) is H, F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, SR 10 , -R8-O-R 10 , -R8-S-R 10, R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocycle), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8-CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), C(O)NH(CH3), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10)、a straight-chain or branched-chain, substituted or unsubstituted alkyl or methyl having 1 to 5 carbon atoms, a straight-chain or branched-chain, substituted or unsubstituted alkenyl having 1 to 5 carbon atoms, a straight-chain or branched-chain having 1 to 5 carbon atoms or a cyclic haloalkyl having 3 to 8 carbon atoms, a straight-chain or branched-chain having 1 to 5 carbon atoms or a cyclic alkoxy having 3 to 8 carbon atoms (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), a straight-chain or branched-chain thioalkyl having 1 to 5 carbon atoms, a straight-chain or branched-chain thioalkoxy having 1 to 5 carbon atoms, a straight-chain or branched-chain haloalkoxy having 1 to 5 carbon atoms, a straight-chain or branched-chain alkoxyalkyl having 1 to 5 carbon atoms, a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms, a substituted or unsubstituted 4- to 6-membered heterocyclic ring, a substituted or unsubstituted aryl, or a substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is F, Cl, Br, I, a straight-chain or branched-chain alkyl having 1 to 5 carbon atoms, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-alkyl, C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted cycloalkyl having 3 to 8 carbon atoms (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and is further substituted with at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention.

[0191] In some embodiments, R7 of Structural Formulas I, I(a) - I(c), I(i), I(j), I(k), and / or I(n) is H. In some embodiments, R7 is F. In some embodiments, R7 is Cl. In some embodiments, R7 is Br. In some embodiments, R7 is I. In some embodiments, R7 is OH. In some embodiments, R7 is O - R 20 . In some embodiments, R7 is CF3. In some embodiments, R7 is CN. In some embodiments, R7 is NH2. In some embodiments, R7 is NHR. In some embodiments, R7 is N(R)2. In some embodiments, R7 is NH(R 10 ). In some embodiments, R7 is N(R 10 )(R 11 ). In some embodiments, R7 is NHC(O) - R 10 . In some embodiments, R7 is COOH. In some embodiments, R7 is -C(O)Ph. In some embodiments, R7 is C(O)O - R 10 . In some embodiments, R7 is C(O)H. In some embodiments, R7 is C(O) - R 10 . In some embodiments, R7 is a C1 - C5 straight - or branched - chain C(O) - haloalkyl. In some embodiments, R7 is -C(O)NH2. In some embodiments, R7 is C(O)NHR. In some embodiments, C(O)NHR is C(O)NH(CH3). In some embodiments, R7 is C(O)N(R 10 )(R 11 ). In some embodiments, C(O)N(R 10 )(R 11) is C(O)NH(CH3), C(O)NH(CH2CH2OCH3), or C(O)NH(CH2CH2OH). Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is SO2R. In some embodiments, R7 is a straight-chain or branched-chain substituted or unsubstituted alkyl of C1-C5. In some embodiments, the alkyl is methylimidazole, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, or hexyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is a straight-chain or branched-chain or cyclic haloalkyl of C1-C5 or C3-C8. In some embodiments, R7 is a straight-chain haloalkyl of C1-C5. In some embodiments, the haloalkyl is CHF2. In some embodiments, R7 is a branched-chain haloalkyl of C1-C5. In some embodiments, R7 is a cyclic haloalkyl of C3-C8. In some embodiments, R7 is a straight-chain or branched-chain or cyclic alkoxy of C1-C5, and optionally, at least one methylene group (CH2) of the alkoxy is replaced by an oxygen atom. In some embodiments, R7 is a straight-chain alkoxy of C1-C5. In some embodiments, the alkoxy is methoxy. In some embodiments, the alkoxy is ethoxy. In some embodiments, R7 is a branched-chain alkoxy of C1-C5. In some embodiments, R7 is a cyclic alkoxy of C3-C8. In some embodiments, R7 is a straight-chain or branched-chain thioalkyl of C1-C5. In some embodiments, R7 is a straight-chain or branched-chain haloalkoxy of C1-C5. In some embodiments, R7 is a straight-chain haloalkoxy of C1-C5. In some embodiments, R7 is a branched-chain haloalkoxy of C1-C5. In some embodiments, R7 is a straight-chain or branched-chain alkoxyalkyl of C1-C5. In some embodiments, R7 is a substituted or unsubstituted cycloalkyl of C3-C8.In some embodiments, the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is a substituted or unsubstituted 3- to 8-membered heterocyclic ring. In some embodiments, R7 is an unsubstituted 3- to 8-membered heterocyclic ring. In some embodiments, R7 is a substituted 3- to 8-membered heterocyclic ring. In some embodiments, R7 is a substituted or unsubstituted 4- to 7-membered heterocyclic ring. In some embodiments, R7 is an unsubstituted 4- to 7-membered heterocyclic ring. In some embodiments, R7 is a substituted 4- to 7-membered heterocyclic ring. In some embodiments, the heterocyclic ring is morpholine (e.g., 2- or 3-morpholine), tetrahydrofuran, tetrahydropyran, oxetane, oxetan-3-ol, pyrrolidine, pyrrolidin-3-ol, 1-methylpyrrolidine, pyrrolidin-2-one, pyrrolidinone, imidazole, pyrazole, piperazine, piperidine, piperidin-4-ol, piperidine-4-carbonitrile, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, pyridine, or 1-methylpyridine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is R8-(substituted or unsubstituted, monocyclic, fused-ring, or spiro 3- to 8-membered heterocyclic ring). In some embodiments, R7 is R8-(unsubstituted monocyclic 3- to 8-membered heterocyclic ring). In some embodiments, R7 is R8-(unsubstituted fused-ring 3- to 8-membered heterocyclic ring). In some embodiments, R7 is R8-(unsubstituted spiro 3- to 8-membered heterocyclic ring). In some embodiments, R7 is R8-(substituted monocyclic 3- to 8-membered heterocyclic ring). In some embodiments, R7 is R8-(substituted fused-ring 3- to 8-membered heterocyclic ring). In some embodiments, R7 is R8-(substituted spiro 3- to 8-membered heterocyclic ring). In some embodiments, the heterocyclic ring may be saturated. In some embodiments, the heterocyclic ring may be unsaturated. In some embodiments, the heterocyclic ring may be aromatic.In some embodiments, R7 is a substituted or unsubstituted aryl. In some embodiments, R7 is phenyl. In some embodiments, R7 is F, Cl, Br, I, a C1-C5 straight-chain or branched-chain alkyl, OH, an alkoxy (e.g., OMe), an amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R. 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and may be further substituted with at least one substituent selected from the group consisting of. Each corresponds to a separate embodiment of the present invention.

[0192] In some embodiments, R7 of structural formulas I, I(a) to I(c), I(i), I(j), I(k), and / or I(n) is O-R 20It is. In some embodiments, R7 is a substituted or unsubstituted 4- to 7-membered heterocyclic ring. In some embodiments, R7 is an unsubstituted 4- to 7-membered heterocyclic ring. In some embodiments, R7 is a substituted 4- to 7-membered heterocyclic ring. In some embodiments, the heterocyclic ring is morpholine (e.g., 2- or 3-morpholine), pyran, oxetane, pyrrolidine, pyrrolidin-3-ol, tetrahydrofuran, imidazole, piperazine, piperidine, piperidin-4-ol, dioxazole, triazole, pyridine, 1-methylpyridine, or 2-oxopyrrolidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7 is a substituted or unsubstituted aryl. In some embodiments, R7 is phenyl. In some embodiments, R7 is F, Cl, Br, I, a C1-C5 straight-chain or branched alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and may be further substituted with at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention.

[0193] In some embodiments, R7 of structural formulas I, I(a)-(c), I(i), I(j), I(k), and / or I(n) is not H, F, Cl, a C1-C5 straight-chain or branched or C3-C8 cyclic alkoxy, a C1-C5 straight-chain or branched haloalkoxy, or a C1-C5 substituted or unsubstituted straight-chain or branched alkyl.

[0194] In some embodiments, R7 of Structural Formulas I, I(a) - I(c), I(i), I(j), I(k), and / or I(n) is represented by Structural Formula A below.

[0195]

Chemical Formula

[0196] In the formula, X1 is N or O; R1 and R2 are each independently H, F, Cl, Br, I, OH, SH, CF3, a substituted or unsubstituted C1 - C5 alkyl, a linear or branched C1 - C5 or cyclic C3 - C8 haloalkyl, a substituted or unsubstituted linear or branched C1 - C5 or cyclic C3 - C8 alkoxy; or, R1 and R2 are bonded to each other to form =O or a C3 - C8 carbocyclic or heterocyclic ring (e.g., cyclopropyl); R3 and R4 are each independently H, Me, a substituted or unsubstituted C1 - C5 alkyl (e.g., methoxyethyl, methylaminoethyl, aminoethyl), -R8 - O - R 10 (e.g., (CH2)2 - O - CH3), R8 - N(R 10 )(R 11 )(e.g., (CH2)2 - NH(CH3)), a substituted or unsubstituted C3 - C8 cycloalkyl (e.g., cyclopropyl), a substituted or unsubstituted 5 - 6 membered heterocyclic ring (e.g., pyrrolidine, methylpyrrolidine, piperidine), or, R 20 ; R3 and R4 are bonded to each other to form a 3 - 8 membered heterocyclic ring (e.g., pyrrolidine, 2 - oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); or, R2 and R4 are joined to each other to form a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocyclic or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidin-2-one, pyridine, piperidine, tetrahydrofuran, tetrahydrothiophene, cyclopropyl, oxetane, imidazole, pyrimidine, triazole, oxadiazole, pyrazole) (however, when the ring is an aromatic ring, R1 and / or R3 do not exist). However, when X1 is O, R4 does not exist.

[0197] In some embodiments, X1 of Structural Formula A is N. In other embodiments, X1 is O.

[0198] In some embodiments, R1 of Structural Formula A is H. In other embodiments, R1 is F. In other embodiments, R1 is CF3.

[0199] In some embodiments, R2 of Structural Formula A is H. In other embodiments, R2 is F. In other embodiments, R2 is CF3.

[0200] In some embodiments, R1 and R2 of Structural Formula A are joined to each other to form =O. In other embodiments, R1 and R2 are joined to each other to form a C3-C8 carbocyclic or heterocyclic ring. In other embodiments, R1 and R2 are joined to each other to form a C3-C8 carbocyclic ring. In some embodiments, the carbocyclic ring is cyclopropyl. In other embodiments, R1 and R2 are joined to each other to form a 3- to 8-membered heterocyclic ring.

[0201] In some embodiments, R1 and R2 of Structural Formula A of Structural Formulas I, I(a)~I(c), I(i), and / or I(k)~I(n) are not joined to each other to form =O.

[0202] In some embodiments, R3 of Structural Formula A is H. In some embodiments, R3 is methyl. In some embodiments, R3 is a C1-C5 substituted or unsubstituted alkyl. In some embodiments, the alkyl is methoxyethylene, methylaminoethylene, or aminoethylene. Each corresponds to a separate embodiment of the present invention. In some embodiments, R3 is a C3-C8 substituted or unsubstituted cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, R3 is a substituted or unsubstituted 5- to 7-membered heterocyclic ring. In some embodiments, the heterocyclic ring is pyrrolidine, methylpyrrolidine, or piperidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R3 is R as defined below 20 is.

[0203] In some embodiments, R4 of Structural Formula A is H. In some embodiments, R4 is methyl. In some embodiments, R4 is a C1-C5 substituted or unsubstituted alkyl. In some embodiments, the alkyl is methoxyethylene, methylaminoethylene, or aminoethylene. Each corresponds to a separate embodiment of the present invention. In some embodiments, R4 is a C3-C8 substituted or unsubstituted cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, R4 is a substituted or unsubstituted 5- to 7-membered heterocyclic ring. In some embodiments, the heterocyclic ring is pyrrolidine, methylpyrrolidine, or piperidine. Each corresponds to a separate embodiment of the present invention. In some embodiments, R4 is R as defined hereinbelow 20 is.

[0204] In some embodiments, R3 and R4 of Structural Formula A are bonded to each other to form a 3- to 8-membered heterocyclic ring. In some embodiments, the heterocyclic ring is imidazole, pyrrolidine, 2-oxopyrrolidine, piperidine, morpholine, or piperazine. Each corresponds to a separate embodiment of the present invention.

[0205] In some embodiments, when X1 in Structural Formula A is O, R4 does not exist.

[0206] In some embodiments, R7 of Structural Formulas I, I(a)~I(c), I(i), I(j), I(k), and / or I(n) is O-R 20 , a substituted or unsubstituted 4- to 7-membered heterocyclic ring (e.g., morpholine, pyran, oxetane, pyrrolidine, imidazole, piperazine, piperidine, dioxazole, triazole, 2-oxopyrrolidine), or a substituted or unsubstituted aryl. In some embodiments, R7 of Structural Formulas I, I(a)~I(c), I(i), I(j), I(k), and / or I(n) is represented by Structural Formula A, and X1, R1, R2, R3, and R4 in the formula are as defined above, except that R1 and R2 cannot be bonded to each other to form =O.

[0207] In some embodiments, R7´ of Structural Formulas I and / or I(a)~I(n) is not H.

[0208] In some embodiments, R7´ of Structural Formulas I and / or I(a)~I(n) is H. In some embodiments, R7´ of Structural Formulas I and / or I(a)~I(n) is F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocyclic ring), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8-CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11)、 COOH, -C(O)Ph, C(O)O-R 10 、 R8-C(O)-R 10 、 C(O)H, C(O)-R 10 、 a C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 )、 SO2R, SO2N(R 10 )(R 11 )、 CH(CF3)(NH-R 10 )、 a C1-C5 substituted or unsubstituted straight-chain or branched alkyl, isopropyl, methyl, ethyl, a C1-C5 substituted or unsubstituted straight-chain or branched alkenyl, a C1-C5 straight-chain or branched or C3-C8 cyclic haloalkyl, a C1-C5 straight-chain or branched or C3-C8 cyclic alkoxy (optionally, at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), a C1-C5 straight-chain or branched thioalkoxy, a C1-C5 straight-chain or branched haloalkoxy, a C1-C5 straight-chain or branched alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, cyclohexyl, a substituted or unsubstituted 3- to 8-membered heterocyclic ring, a substituted or unsubstituted aryl, a substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´ is F, Cl, Br, I, a C1-C5 straight-chain or branched alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 )、 N(R 10 )(R 11) (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and is further substituted with at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention.

[0209] In some embodiments, R7' of Structural Formulas I and / or I(a) - I(n) is H. In some embodiments, R7' is F. In some embodiments, R7' is Cl. In some embodiments, R7' is Br. In some embodiments, R7' is I. In some embodiments, R7' is CF3. In some embodiments, R7' is a C1 - C5 substituted or unsubstituted straight or branched alkyl. In some embodiments, R7' is a C1 - C5 straight or branched unsubstituted alkyl. In some embodiments, the alkyl is isopropyl, methyl, or ethyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7' is a C1 - C5 straight or branched substituted alkyl. In some embodiments, R7' is isopropyl. In some embodiments, R7' is methyl. In some embodiments, R7' is ethyl. In some embodiments, R7' is a C1 - C5 straight or branched or C3 - C8 cyclic haloalkyl. In some embodiments, R7' is a C1 - C5 straight or branched haloalkyl. In some embodiments, the haloalkyl is CHF2. In some embodiments, R7' is a C3 - C8 cyclic haloalkyl. In some embodiments, R7' is a C3 - C8 substituted or unsubstituted cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, the cycloalkyl is cyclohexyl. In some embodiments, R7' is a substituted or unsubstituted aryl. In some embodiments, R7' is phenyl. In some embodiments, R7' is a C1 - C5 straight or branched, or C3 - C8 cyclic alkoxy. In some embodiments, R7' is methoxy.

[0210] In some embodiments, R7 and R7′ of Structural Formulas I, I(a) - I(c), and / or I(i) - I(n) are joined to each other to form a substituted or unsubstituted saturated, unsaturated, or aromatic 5 - or 6 - membered carbocyclic or heterocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form an unsubstituted saturated or unsaturated 5 - membered carbocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form an unsubstituted saturated or unsaturated 6 - membered carbocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form a substituted saturated or unsaturated 5 - membered carbocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form a substituted saturated or unsaturated 6 - membered carbocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form a substituted or unsubstituted aromatic 6 - membered carbocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form a substituted or unsubstituted aromatic 5 - or 6 - membered heterocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form a substituted or unsubstituted 5 - or 6 - membered heterocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form a substituted or unsubstituted 6 - membered heterocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form piperidine. In some embodiments, R7 and R7′ are joined to each other to form tetrahydropyran. In some embodiments, R7 and R7′ are joined to each other to form a substituted or unsubstituted 5 - membered heterocyclic ring. In some embodiments, R7 and R7′ are joined to each other to form pyrrolidine. In some embodiments, R7 and R7′ are joined to each other to form tetrahydrofuran.

[0211] In some embodiments, R7 and R7´ in Structural Formulas I, I(a) - I(c), I(i) - I(k), and / or I(n) are different from each other. In some embodiments, R7 and R7´ in Structural Formula I(c) are not H, F, Cl, a straight-chain or branched C1-C5 or cyclic C3-C8 alkoxy, a straight-chain or branched C1-C5 haloalkoxy, or a substituted or unsubstituted straight-chain or branched C1-C5 alkyl. Each corresponds to a separate embodiment of the present invention.

[0212] In some embodiments, R7´´ in Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) is not H.

[0213] In some embodiments, R7´´ in Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) is H. In some embodiments, R7´´ in Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) is F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3 - 8 membered heterocycle), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a straight-chain or branched C1-C5 C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11)、SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10 ), a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkenyl, a C1-C5 straight-chain or branched-chain, or a C3-C8 cyclic haloalkyl, a C1-C5 straight-chain or branched-chain, or a C3-C8 cyclic alkoxy (optionally at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), a C1-C5 straight-chain or branched-chain thioalkoxy, a C1-C5 straight-chain or branched-chain haloalkoxy, a C1-C5 straight-chain or branched-chain alkoxyalkyl, a C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, cyclohexyl, a substituted or unsubstituted 3- to 8-membered heterocyclic ring, a substituted or unsubstituted aryl, phenyl, or a substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´´ is F, Cl, Br, I, a C1-C5 straight-chain or branched-chain alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and is further substituted with at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention.

[0214] In some embodiments, R7´´ of Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) is H. In some embodiments, R7´´ is F. In some embodiments, R7´´ is Cl. In some embodiments, R7´´ is Br. In some embodiments, R7´´ is I. In some embodiments, R7´´ is CF3. In some embodiments, R7´´ is a C1-C5 straight-chain or branched-chain, substituted or unsubstituted alkyl. In some embodiments, R7´´ is a C1-C5 straight-chain or branched-chain unsubstituted alkyl. In some embodiments, the alkyl is isopropyl, methyl, or ethyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7´´ is a C1-C5 straight-chain or branched-chain substituted alkyl. In some embodiments, R7´´ is isopropyl. In some embodiments, R7´´ is methyl. In some embodiments, R7´´ is ethyl. In some embodiments, R7´´ is a C1-C5 straight-chain or branched-chain, or C3-C8 cyclic haloalkyl. In some embodiments, R7´´ is a C1-C5 straight-chain or branched-chain haloalkyl. In some embodiments, the haloalkyl is CHF2. In some embodiments, R7´´ is a C3-C8 cyclic haloalkyl. In some embodiments, R7´´ is a C3-C8 substituted or unsubstituted cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, the cycloalkyl is cyclohexyl. In some embodiments, R7´´ is a substituted or unsubstituted aryl. In some embodiments, R7´´ is phenyl. In some embodiments, R7´´ is a C1-C5 straight-chain or branched-chain, or C3-C8 cyclic alkoxy. In some embodiments, R7´´ is methoxy.

[0215] In some embodiments, R7´´´ of Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) is not H.

[0216] In some embodiments, R7´´´ of structural formulas I(a), I(c), I(e), and / or I(f) - I(n) is H. In some embodiments, R7´´´ of structural formula I(i) is F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocycle), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10), a straight-chain or branched-chain C1-C5 substituted or unsubstituted alkyl, a straight-chain or branched-chain C1-C5 substituted or unsubstituted alkenyl, a straight-chain or branched-chain C1-C5, or a cyclic C3-C8 haloalkyl, a straight-chain or branched-chain C1-C5, or a cyclic C3-C8 alkoxy (optionally at least one methylene group (CH2) in the alkoxy is replaced by an oxygen atom), a straight-chain or branched-chain C1-C5 thioalkoxy, a straight-chain or branched-chain C1-C5 haloalkoxy, a straight-chain or branched-chain C1-C5 alkoxyalkyl, a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, cyclohexyl, a substituted or unsubstituted 3- to 8-membered heterocyclic ring, a substituted or unsubstituted aryl, phenyl, or a substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7''' is cyclopropyl. In some embodiments, R7''' is F, Cl, Br, I, a straight-chain or branched-chain C1-C5 alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2 and is further substituted with at least one substituent selected from. Each corresponds to a separate embodiment of the present invention.

[0217] In some embodiments, R7′′′ of structural formulas I(a), I(c), I(e), and / or I(f) - I(n) is H. In some embodiments, R7′′′ is F. In some embodiments, R7′′′ is Cl. In some embodiments, R7′′′ is Br. In some embodiments, R7′′′ is I. In some embodiments, R7′′′ is CF3. In some embodiments, R7′′′ is a linear or branched, substituted or unsubstituted C1-C5 alkyl. In some embodiments, R7′′′ is a linear or branched unsubstituted C1-C5 alkyl. In some embodiments, the alkyl is isopropyl, methyl, ethyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7′′′ is a linear or branched substituted C1-C5 alkyl. In some embodiments, R7′′′ is isopropyl. In some embodiments, R7′′′ is methyl. In some embodiments, R7′′′ is ethyl. In some embodiments, R7′′′ is a linear or branched C1-C5 or cyclic C3-C8 haloalkyl. In some embodiments, R7′′′ is a linear or branched C1-C5 haloalkyl. In some embodiments, the haloalkyl is CHF2. In some embodiments, R7′′′ is a cyclic C3-C8 haloalkyl. In some embodiments, R7′′′ is a substituted or unsubstituted C3-C8 cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, the cycloalkyl is cyclohexyl. In some embodiments, R7′′′ is a substituted or unsubstituted aryl. In some embodiments, R7′′′ is phenyl. In some embodiments, R7′′′ is a linear or branched C1-C5 or cyclic C3-C8 alkoxy. In some embodiments, R7′′′ is methoxy.

[0218] In some embodiments, R7′′′′ of structural formulas I(a), I(c), I(e), and / or I(f) - I(n) is not H.

[0219] In some embodiments, R7´´´´ of Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) is H. In some embodiments, R7´´´´ of Structural Formula I(i) is F, Cl, Br, I, OH, O-R 20 , SH, R8-OH, R8-SH, -R8-O-R 10 , R8-(C3-C8 cycloalkyl), R8-(3- to 8-membered heterocycle), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R 10 ), N(R 10 )(R 11 ), R8-N(R 10 )(R 11 ), R9-R8-N(R 10 )(R 11 ), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10 , NHCO-N(R 10 )(R 11 ), COOH, -C(O)Ph, C(O)O-R 10 , R8-C(O)-R 10 , C(O)H, C(O)-R 10 , a C1-C5 straight-chain or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R 10 )(R 11 ), SO2R, SO2N(R 10 )(R 11 ), CH(CF3)(NH-R 10) C1-C5 linear or branched, substituted or unsubstituted alkyl, C1-C5 linear or branched, substituted or unsubstituted alkenyl, C1-C5 linear or branched, or C3-C8 cyclic haloalkyl, C1-C5 linear or branched, or C3-C8 cyclic alkoxy (optionally at least one methylene group (CH2) in the alkoxy is substituted by an oxygen atom), C1-C5 linear or branched thioalkoxy, C1-C5 linear or branched haloalkoxy, C1-C5 linear or branched alkoxyalkyl, C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, cyclohexyl, substituted or unsubstituted 3- to 8-membered heterocyclic ring, substituted or unsubstituted aryl, phenyl, or substituted or unsubstituted benzyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7'''' is F, Cl, Br, I, C1-C5 linear or branched alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 ) N(R 10 )(R 11 ) (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2 and is further substituted with at least one substituent selected from. Each corresponds to a separate embodiment of the present invention.

[0220] In some embodiments, R7′′′′ of Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) is H. In some embodiments, R7′′′′ is F. In some embodiments, R7′′′′ is Cl. In some embodiments, R7′′′′ is Br. In some embodiments, R7′′′′ is I. In some embodiments, R7′′′′ is CF3. In some embodiments, R7′′′′ is a straight-chain or branched-chain, substituted or unsubstituted C1 - C5 alkyl. In some embodiments, R7′′′′ is a straight-chain or branched-chain unsubstituted C1 - C5 alkyl. In some embodiments, the alkyl is isopropyl, methyl, ethyl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R7′′′′ is a straight-chain or branched-chain, substituted C1 - C5 alkyl. In some embodiments, R7′′′′ is isopropyl. In some embodiments, R7′′′′ is methyl. In some embodiments, R7′′′′ is ethyl. In some embodiments, R7′′′′ is a straight-chain or branched-chain C1 - C5, or C3 - C8 cyclic haloalkyl. In some embodiments, R7′′′′ is a straight-chain or branched-chain C1 - C5 haloalkyl. In some embodiments, the haloalkyl is CHF2. In some embodiments, R7′′′′ is a C3 - C8 cyclic haloalkyl. In some embodiments, R7′′′′ is a substituted or unsubstituted C3 - C8 cycloalkyl. In some embodiments, the cycloalkyl is cyclopropyl. In some embodiments, the cycloalkyl is cyclohexyl. In some embodiments, R7′′′′ is a substituted or unsubstituted aryl. In some embodiments, R7′′′′ is phenyl. In some embodiments, R7′′′′ is a straight-chain or branched-chain C1 - C5, or C3 - C8 cyclic alkoxy. In some embodiments, R7′′′′ is methoxy.

[0221] In some embodiments, R7′ and R7″ of Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) are joined to each other to form a substituted or unsubstituted saturated, unsaturated, or aromatic 3 - 8 membered carbocyclic or heterocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form an unsubstituted saturated or unsaturated 5 - membered carbocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form cyclopentane. In some embodiments, R7′ and R7″ are joined to each other to form an unsubstituted saturated or unsaturated 6 - membered carbocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form cyclohexane. In some embodiments, R7′ and R7″ are joined to each other to form a substituted saturated or unsaturated 5 - membered carbocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form a substituted saturated or unsaturated 6 - membered carbocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form a substituted or unsubstituted aromatic 6 - membered carbocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form a substituted or unsubstituted 5 - or 6 - membered aromatic heterocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form a substituted or unsubstituted 5 - or 6 - membered heterocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form a substituted or unsubstituted 6 - membered heterocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form piperidine. In some embodiments, R7′ and R7″ are joined to each other to form tetrahydropyran. In some embodiments, R7′ and R7″ are joined to each other to form a substituted or unsubstituted 5 - membered heterocyclic ring. In some embodiments, R7′ and R7″ are joined to each other to form tetrahydrofuran. In some embodiments, R7′ and R7″ are joined to each other to form pyrrolidine.

[0222] In some embodiments, R7' and R7'' of Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) are different from each other. In some embodiments, R7' and R7'' of Structural Formulas I(a), I(c), I(e), and / or I(f) - I(n) are not H, F, Cl, a C1-C5 straight or branched, or C3-C8 cyclic alkoxy, a C1-C5 straight or branched haloalkoxy, or a C1-C5 straight or branched, substituted or unsubstituted alkyl. Each represents a separate embodiment of this invention.

[0223] In some embodiments, R7´´ and R7 of Structural Formulas I(a), I(c), I(i), I(j)-I(k), and / or I(n) are bonded to each other to form a substituted or unsubstituted, saturated, unsaturated or aromatic, carbocyclic or heterocyclic 3- to 8-membered ring. In some embodiments, R7´´ and R7 are bonded to each other to form an unsubstituted saturated or unsaturated 5-membered carbocyclic ring. In some embodiments, R7´´ and R7 are bonded to each other to form cyclopentane. In some embodiments, R7´´ and R7 are bonded to each other to form an unsubstituted saturated or unsaturated 6-membered carbocyclic ring. In some embodiments, R7´´ and R7 are bonded to each other to form cyclohexane. In some embodiments, R7´´ and R7 are bonded to each other to form a substituted saturated or unsaturated 5-membered carbocyclic ring. In some embodiments, R7´´ and R7 are bonded to each other to form a substituted saturated or unsaturated 6-membered carbocyclic ring. In some embodiments, R7´´ and R7 are bonded to each other to form a substituted or unsubstituted aromatic 6-membered carbocyclic ring. In some embodiments, R7´´ and R7 are bonded to each other to form a substituted or unsubstituted aromatic 5- or 6-membered heterocyclic ring. In some embodiments, R7´´ and R7 are bonded to each other to form a substituted or unsubstituted 5- or 6-membered heterocyclic ring. In some embodiments, R7´´ and R7 are bonded to each other to form a substituted or unsubstituted 6-membered heterocyclic ring. In some embodiments, R7´´ and R7 are bonded to each other to form piperidine. In some embodiments, R7´´ and R7 are bonded to each other to form tetrahydropyran. In some embodiments, R7´´ and R7 are bonded to each other to form a substituted or unsubstituted 5-membered heterocyclic ring. In some embodiments, R7´´ and R7 are bonded to each other to form tetrahydrofuran. In some embodiments, R7´´ and R7 are bonded to each other to form pyrrolidine.

[0224] In some embodiments, R7'' and R7 of Structural Formulas I(a), I(c), I(i), I(j)-I(k), and / or I(n) are different from each other. In some embodiments, R7'' and R7 of I(a), I(c), I(i), I(j)-I(k) and / or I(n) are not H, F, Cl, C1-C5 linear or branched, or C3-C8 cyclic alkoxy, C1-C5 linear or branched haloalkoxy, or C1-C5 linear or branched, substituted or unsubstituted alkyl. Each corresponds to a separate embodiment of the invention.

[0225] In some embodiments, R7 and R7''' of Structural Formulas I(a), I(c), I(i), I(j) - I(k), and / or I(n) are joined to each other to form a substituted or unsubstituted, saturated, unsaturated or aromatic, carbocyclic or heterocyclic 3- to 8-membered ring. In some embodiments, R7 and R7''' are joined to each other to form an unsubstituted saturated or unsaturated 5-membered carbocyclic ring. In some embodiments, R7 and R7''' are joined to each other to form an unsubstituted saturated or unsaturated 6-membered carbocyclic ring. In some embodiments, R7 and R7''' are joined to each other to form a substituted saturated or unsaturated 5-membered carbocyclic ring. In some embodiments, R7 and R7''' are joined to each other to form a substituted saturated or unsaturated 6-membered carbocyclic ring. In some embodiments, R7 and R7''' are joined to each other to form a substituted or unsubstituted aromatic 6-membered carbocyclic ring. In some embodiments, R7 and R7''' are joined to each other to form a substituted or unsubstituted aromatic 5- or 6-membered heterocyclic ring. In some embodiments, R7 and R7''' are joined to each other to form a substituted or unsubstituted 5- or 6-membered heterocyclic ring. In some embodiments, R7 and R7''' are joined to each other to form a substituted or unsubstituted 6-membered heterocyclic ring. In some embodiments, R7 and R7''' are joined to each other to form piperidine. In some embodiments, R7 and R7''' are joined to each other to form tetrahydrofuran. In some embodiments, R7 and R7''' are joined to each other to form tetrahydropyran. In some embodiments, R7 and R7''' are joined to each other to form a substituted or unsubstituted 5-membered heterocyclic ring. In some embodiments, R7 and R7''' are joined to each other to form pyrrolidine. In some embodiments, R7 and R7''' are joined to each other to form cyclopentane. In some embodiments, R7 and R7''' are joined to each other to form cyclohexane.

[0226] In some embodiments, R7 and R7''' of Structural Formulas I(a), I(c), I(i), I(j) - I(k), and / or I(n) are different from each other. In some embodiments, R7 and R7''' of Structural Formula I(i) are not H, F, Cl, C1-C5 straight or branched chain, or C3-C8 cyclic alkoxy, C1-C5 straight or branched chain haloalkoxy, or C1-C5 straight or branched chain, substituted or unsubstituted alkyl. Each represents a separate embodiment of this invention.

[0227] In some embodiments, R7''' and R7'''' of Structural Formulas I(a), I(c), I(i), I(j)-I(k), and / or I(n) are joined to each other to form a substituted or unsubstituted, saturated, unsaturated or aromatic, carbocyclic or heterocyclic 3- to 8-membered ring. In some embodiments, R7''' and R7'''' are joined to each other to form an unsubstituted saturated or unsaturated 5-membered carbocyclic ring. In some embodiments, R7''' and R7'''' are joined to each other to form an unsubstituted saturated or unsaturated 6-membered carbocyclic ring. In some embodiments, R7''' and R7'''' are joined to each other to form a substituted saturated or unsaturated 5-membered carbocyclic ring. In some embodiments, R7''' and R7'''' are joined to each other to form a substituted saturated or unsaturated 6-membered carbocyclic ring. In some embodiments, R7''' and R7'''' are joined to each other to form a substituted or unsubstituted aromatic 6-membered carbocyclic ring. In some embodiments, R7''' and R7'''' are joined to each other to form a substituted or unsubstituted aromatic 5- or 6-membered heterocyclic ring. In some embodiments, R7''' and R7'''' are joined to each other to form a substituted or unsubstituted 5- or 6-membered heterocyclic ring. In some embodiments, R7''' and R7'''' are joined to each other to form a substituted or unsubstituted 6-membered heterocyclic ring. In some embodiments, R7''' and R7'''' are joined to each other to form piperidine. In some embodiments, R7''' and R7'''' are joined to each other to form tetrahydrofuran. In some embodiments, R7''' and R7'''' are joined to each other to form tetrahydropyran. In some embodiments, R7''' and R7'''' are joined to each other to form a substituted or unsubstituted 5-membered heterocyclic ring. In some embodiments, R7''' and R7'''' are joined to each other to form pyrrolidine. In some embodiments, R7''' and R7'''' are joined to each other to form cyclopentane. In some embodiments, R7''' and R7'''' are joined to each other to form cyclohexane.

[0228] In some embodiments, R7''' and R7'''' of Structural Formulas I(a), I(c), and / or I(e)-I(n) are different from each other. In some embodiments, R7''' and R7'''' of Structural Formula I(i) are not H, F, Cl, a linear or branched C1-C5, or C3-C8 cyclic alkoxy, a linear or branched C1-C5 haloalkoxy, or a linear or branched C1-C5, substituted or unsubstituted alkyl. Each represents a separate embodiment of this invention.

[0229] In some embodiments, at least one of R7', R7'', R7''', and R7'''' of Structural Formulas I(a), I(c), and / or I(e)-I(n) is not H. In some embodiments, at least two of R7', R7'', R7''', and R7'''' of Structural Formulas I(a), I(c), and / or I(e)-I(n) are not H. In some embodiments, at least three of R7', R7'', R7''', and R7'''' of Structural Formulas I(a), I(c), and / or I(e)-I(n) are not H.

[0230] In some embodiments, at least one of R7, R7', R7'', R7''', and R7'''' of Structural Formulas I(a), I(c), I(i), I(j)-I(k), and / or I(n) is not H. In some embodiments, at least two of R7, R7', R7'', R7''', and R7'''' of Structural Formulas I(a), I(c), I(i), I(j)-I(k), and / or I(n) are not H. In some embodiments, at least three of R7, R7', R7'', R7''', and R7'''' of Structural Formulas I(a), I(c), I(i), I(j)-I(k), and / or I(n) are not H.

[0231] In some embodiments, R of Structural Formulas I and / or I(a)-I(n) 30 is H, R 20 , F, Cl, Br, I, OH, SH, OH, alkoxy, N(R)2, NH(R 10 ), N(R10 )(R 11 ), CF3, CN, NO2, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl, a C1-C5 straight-chain or branched-chain alkoxy, a C1-C5 straight-chain or branched-chain haloalkyl, an R8-aryl, -R8-O-R8-O-R 10 , -R8-O-R 10 , -R8-R 10 , a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl. Each corresponds to a separate embodiment of the present invention. In some embodiments, R 30 is further F, Cl, Br, I, a C1-C5 straight-chain or branched-chain alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and is substituted with at least one substituent selected therefrom. Each corresponds to a separate embodiment of the present invention. In some embodiments, R 30 is H. In some embodiments, R 30 is R 20 .

[0232] In some embodiments, R 50 of structural formulas I(b), I(c), I(f), I(h), I(l), and / or I(m) is H, R 20 , F, Cl, Br, I, OH, SH, N(R)2, NH(R 10 ), N(R 10 )(R 11)、CF3, CN, NO2, a linear or branched, substituted or unsubstituted C1-C5 alkyl, a linear or branched C1-C5 alkoxy, a linear or branched C1-C5 haloalkyl, -R8-R 10 (e.g., (CH2)2-O-CH3), a substituted or unsubstituted aryl (e.g., phenyl), a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)). Each corresponds to a separate embodiment of the present invention. In some embodiments, R 50 is F, Cl, Br, I, a linear or branched C1-C5 alkyl, OH, an alkoxy (e.g., OMe), an amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 ), N(R 10 )(R 11 ), (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a substituted or unsubstituted C3-C8 cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methylpyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2, and is further substituted with at least one substituent selected from the group consisting of. Each corresponds to a separate embodiment of the present invention. In some embodiments, R 50 is H. In some embodiments, R 50 is F. In some embodiments, R 50 is CF3. In some embodiments, R 50 is CN.

[0233] In some embodiments, the G ring of Structural Formulas I(b), I(c), I(f), I(h), I(l), and / or I(m) is absent. In some embodiments, the G ring is a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring. In some embodiments, the G ring is a substituted 3- to 8-membered carbocyclic ring. In some embodiments, the G ring is an unsubstituted 3- to 8-membered carbocyclic ring. In some embodiments, the G ring is an unsubstituted 4- to 7-membered carbocyclic ring. In some embodiments, the G ring is an unsubstituted 3- to 6-membered carbocyclic ring. In some embodiments, the G ring is cyclobutane. In some embodiments, the G ring is cyclopentane. In some embodiments, the G ring is cyclohexane. In some embodiments, the G ring is a substituted or unsubstituted 3- to 8-membered heterocyclic ring. In some embodiments, the G ring is a substituted 3- to 8-membered heterocyclic ring.

[0234] In some embodiments, R of Structural Formulas I and / or I(a) - I(n) is H, F, Cl, Br, I, OH, SH, OH, COOH, CO(R 10 ), C(O)CH3, NH(R 10 ), NH-CH2-cyclopropyl, N(R 10 )(R 11)、CF3, CN, NO2, a linear or branched C1-C5 alkyl, a linear or branched C1-C5 alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), a substituted or unsubstituted C3-C8 cycloalkyl, cyclopropyl, a linear or branched C1-C5 alkoxy (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), a linear or branched C1-C5 haloalkyl (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R 10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R 10 , O-R8-R 10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R 10 (e.g., (CH2)-cyclopropyl), (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2)-COOH, a substituted or unsubstituted aryl (e.g., phenyl), or a substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)). Each corresponds to a separate embodiment of the present invention. In some embodiments, R is further F, Cl, Br, I, a linear or branched C1-C5 alkyl, OH, alkoxy (e.g., OMe), amide (e.g., C(O)N(R)2), C(O)-pyrrolidine, C(O)-piperidine, N(R)2NH(R 10 ), N(R 10 )(R 11) (e.g., N(CH3)2, NH2), CF3, aryl, phenyl, heteroaryl, a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclobutanol), a substituted or unsubstituted 3- to 8-membered heterocyclic ring (e.g., pyran, oxetane, piperidine, pyrazole, methyl-pyrazole, triazole, imidazole), halophenyl, (benzyloxy)phenyl, CN, and NO2. Each corresponds to a separate embodiment of the present invention. In some embodiments, R is H. In some embodiments, R is F, Cl, Br, or I. In some embodiments, R is NH(R 10) It is. In some embodiments, R is NH-CH2-cyclopropyl. In some embodiments, R is a linear or branched C1-C5 substituted or unsubstituted alkyl. In some embodiments, R is methyl. In some embodiments, R is ethyl. In some embodiments, R is propyl. In some embodiments, R is isopropyl. In some embodiments, R is butyl. In some embodiments, R is a substituted alkyl. In some embodiments, R is CH2-OH. In some embodiments, R is CH2-CH2-OH. In some embodiments, R is a substituted or unsubstituted C3-C8 cycloalkyl. In some embodiments, R is cyclopropyl. In some embodiments, R is a linear or branched C1-C5 alkoxy. In some embodiments, R is methoxy. In some embodiments, R is ethoxy. In some embodiments, R is propoxy. In some embodiments, R is isopropoxy. In some embodiments, R is O-(CH2)-cyclopropyl. In some embodiments, R is O-CH2-methylcyclobutyl. In some embodiments, R is O-CH(CH3)-CH2-O-CH3. In some embodiments, R is O-(CH2CH3). In some embodiments, R is OCHF2. In some embodiments, R is O-(CH2)2-O-CH3. In some embodiments, R is COOH. In some embodiments, R is O-R8-R 10 It is. In some embodiments, R is O-(CH2)2-O-CH3. In some embodiments, R is O-(CH2CH3). In some embodiments, R is -R8-R 10 It is. In some embodiments, R is (CH2)-cyclopropyl. In some embodiments, R is (CH2)-OH. In some embodiments, R is (CH2)2-OH. In some embodiments, R is (CH2)-COOH. In some embodiments, R is OH. In some embodiments, R is CO(R10 ) is.

[0235] In various embodiments, R8 of the compounds of Structural Formulas I and / or I(a) - I(n) is CH2. In some embodiments, R8 is CH2CH2. In some embodiments, R8 is CH2CH2CH2. In some embodiments, R8 is CH2CH2CH2CH2.

[0236] In some embodiments, p of Structural Formulas I and / or I(a) - I(n) is 1. In other embodiments, p is 2. In other embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, p is from 1 to 3. In some embodiments, p is from 1 to 5. In some embodiments, p is from 1 to 10.

[0237] In some embodiments, R9 of Structural Formulas I and / or I(a) - I(n) is C≡C. In some embodiments, R9 is C≡C - C≡C. In some embodiments, R9 is CH=CH. In some embodiments, R9 is CH=CH - CH=CH.

[0238] In some embodiments, q of Structural Formulas I and / or I(a) - I(n) is 2. In some embodiments, q is 4. In some embodiments, q is 6. In some embodiments, q is 8. In some embodiments, q is from 2 to 6.

[0239] In some embodiments, R of Structural Formulas I and / or I(a) - I(n) 10is H, OH, COOH, a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), a C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), a C1-C5 substituted or unsubstituted straight-chain or branched-chain haloalkyl, CH2CF3, a C1-C5 straight-chain or branched-chain alkoxy (e.g., O-CH3), R 20 , C(O)R, or S(O)2R. Each corresponds to a separate embodiment of the present invention. In some embodiments, R 10 is H. In some embodiments, R 10 is a C1-C5 substituted or unsubstituted straight-chain or branched-chain alkyl. In some embodiments, R 10 is a C1-C5 unsubstituted straight-chain or branched-chain alkyl. In other embodiments, R 10 is CH3. In other embodiments, R 10 is CH2CH3. In other embodiments, R 10 is CH2CH2CH3. In some embodiments, R 10 is isopropyl. In some embodiments, R 10 is butyl. In some embodiments, R 10 is isobutyl. In some embodiments, R 10 is t-butyl. In some embodiments, R 10 is pentyl. Isopentyl. Neopentyl. Benzyl. A C1-C5 substituted straight-chain or branched-chain alkyl. In other embodiments, R 10 is CH2-CH2-O-CH3. In some embodiments, R 10 is a C3-C8 substituted or unsubstituted cycloalkyl. In some ...

Claims

1. A compound represented by the following structural formula I(l), or a pharmaceutically acceptable salt thereof, stereoisomer, tautomer, hydrate, N-oxide, reverse amide analog, prodrug, isotopic variant (e.g., deuterated analog), pharmaceutical, or any combination thereof. 【Chemistry 1】 During the ceremony, The W ring can be an aromatic or aromatic ring. If the W ring is an aromatic ring, X2, X3, and X4 are independently CH, C(R), N (e.g., C(CH3), C(O-CH2-cyclopropyl), C(O-CH2-methylcyclobutyl), C(O-CH2-3-methyloxetane), C(NH-CH2-cyclopropyl), C(isopropoxy), C(O-CH(CH3)-CH2-O-CH3), C(CH2CH3), C-iPr, C-CH2-cyclopropyl, C(OCH3), C(OCH2CH3), C(O-(CH2)2-O-CH3), C(OCHF2), C(Cl), C(C(O)CH3), C(O-CH2CH2-O-CH3), C(OH)); X 15 is C; If the W ring is a non-aromatic ring, X2, X3, and X4 are, independently of each other, CH2, CH(R), C(R)2, NH, N(R), O, S, S=O, or SO2 (e.g., CH2); X 15 is CH, C(R), or N (e.g., CH, N); X5, X6, X7, X8, and X9 are independently either nitrogen or carbon atoms. However, if any one of X5, X6, X7, X8, and X9 is nitrogen, then the substituents R7', R7'', R7, R7'''', and R7'''''' do not exist. X10 is N, CH, C(R), or C=O. However, if X10 is C=O, then X11 is N (e.g., C(CH2-OH), C(CH2-CH2-OH), C(NH-CH2-cyclopropyl), C(COOH), C(CH3), C(cyclopropyl), C(isopropoxy)); X 11 is either N or C, provided that if X 11 is N, then X 10 is C = O; The W' ring can be an aromatic or aromatic ring. If the W' ring is an aromatic ring, X12 is S, SO2, O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (e.g., N-CH2-COOH, N-CH2-CH2-OH, N-CH3, N-CH2CH3, N-iPr, N-cyclopropyl, N-CH2-cyclopropyl); If the W' ring is a non-aromatic ring, X 12 is CH=CH, CH=CH(R), C(R)=CH, OCH 2, SCH 2, CH=N, C(R)=N, N=CH, or N=C(R); If both the W ring and the W ring' are aromatic rings, then at least one of X2, X3, and X4 is C(R); X11 is N; or X12 is not S; The F ring is absent, or is a substituted or unsubstituted, saturated or unsaturated, 3- to 8-membered heterocycle or carbocyclic ring (e.g., pyrrolidine, 1-methylpyrrolidine, pyrrolidine-3-ol, pyrrolidine-2-one, pyridine, piperidine, piperidine-4-ol, tetrahydrofuran, morpholine, tetrahydrothiophene, cyclopropyl, oxetane, oxetane-3-ol, imidazole, pyrimidine, triazole, oxadiazole, pyrazole); R1 and R2 are independently H, F, Cl, Br, I, OH, SH, CF3, a C1-C5 substituted or unsubstituted alkyl, a C1-C5 linear or branched or C3-C8 cyclic haloalkyl, or a C1-C5 substituted or unsubstituted linear or branched or C3-C8 cyclic alkoxy; Alternatively, R1 and R2 may bond to each other to form a 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopropyl, oxetane); Alternatively, R2 and R4 may bond to each other to form the F ring as defined above (e.g., pyrrolidine, pyrrolidine-2-one, piperidine, morpholine, pyridine, pyrimidine, triazole, oxadiazole, pyrazole, tetrahydrofuran). However, if the F ring is an aromatic ring, R1 and / or R3 are absent; R3 and R4 are independently H, Me, a C1-C5 substituted or unsubstituted alkyl group (e.g., methoxyethylene, methylaminoethyl, aminoethyl), -R8-O-R10 (e.g., (CH2)2-O-CH3), R8-N(R10)(R11) (e.g., (CH2)2-NH(CH3)), a C3-C8 substituted or unsubstituted cycloalkyl group (e.g., cyclopropyl), a substituted or unsubstituted 5- to 7-membered heterocycle (e.g., pyrrolidine, methylpyrrolidine, piperidine), or R20; Alternatively, R3 and R4 may bond to each other to form a 3- to 8-membered heterocycle (e.g., pyrrolidine, pyrrolidone, 2-oxopyrrolidine, piperidine, morpholine, piperazine, imidazole); X 14 is S, O, N, or CH. If X 14 is CH, there is no F ring, and if X 14 is S or O, R 3 is not present. R5 is H, or a C1-C5 linear or branched alkyl group (e.g., methyl); R6 is H, F, Cl, Br, I, OH, SH, R8-OH, R8-SH, -R8-O-R10 (e.g., CH2-O-CH3, (CH2)2-O-CH3, (CH2)3-O-CH3, (CH2)2-O-CH(CH3)2), R8-S-R10 (e.g., (CH2)3-S-(CH2)2CH3), R8-NHC(O)-R10, -O-R8-R10, R8-(C3-C8 substituted or unsubstituted cycloalkyl) (e.g., CH2-cyclopropyl, CH2-cyclobutanol, CH2 -Difluorocyclopropyl, CH2-methylcyclopropyl, CH2-dimethylaminocyclohexyl, (CH2)2-cyclopentanol, CH2-cyclohexanol), R8-(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused, or spirocyclic heterocycles of 3 to 10 members) (e.g., (CH2)3-piperidine, (CH2)3-4-fluoropiperidine, (CH2)3-pyran, (CH2)2-pyrazole, (CH2)2-imidazole, CH2-tetrahydrofuran, CH2-dioxane, CH2-oxetane, CH2-piperidine, CH2-triazole, CH2-1-oxa-8-azaspiro[4.5]decane, (CH2 ) 3-Diazabicyclo[2.2.1]heptane, CH2-methyl-THF, CH2-ethyl-piperidine, CH2-oxa-azaspirodecane, (CH2)3-dimethylpyrazole, CH2-2-oxo-methylpyrrolidine, CH2-methylazetidine, CH2-azaspiroheptane), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R10), N(R10)(R11), R8-N(R10)(R11) (e.g., (CH2)2-NH2, (CH2)3 -N(CH 2 CH 3 ) 2 , (CH 2 ) 3 -N(CH(CH 3 ) 2 ) 2 , (CH 2 ) 3 -piperidine, (CH 2 ) 3-4-Fluoropiperidine, (CH2)3 -4-Cyanopipeidine, (CH2)4-NH(CH3), (CH2)3-NH-CH3, (CH2)3-NH-CH2CH3, (CH2)3-N(CH2CH3)2, (CH2)3-NH2, (CH2)3-N(CH2CH3)(CH2CF3)), R9-R8-N(R10)(R11) (e.g., (CH2)2-C(O)-piperidine), B(OH)2, -OC(O)CF3, -OCH2Ph, NHC(O)-R 10, NHCO-N(R10)(R11), COOH, -C(O)Ph, C(O)O-R10, R8, -C(O)-R10, C(O)H, C(O)-R10 (e.g., C(O)CH3), C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH2, C(O)NHR, C(O)N(R10)(R11), SO2R, SO2N(R10)(R11), CH(CF3)(NH-R10), C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., CH(CH3)CH2OCH3, CH(CH3) )CH2NH2, CH(CH3)C(O)N(CH3)2, CH2-CH(OH)Ph, (CH2)3N(H)CH2CH3, CH(CH3)(CH2)2OH, CH(CH2OH)(CH2 CH3), (CH2)3-OCH3, (CH2)2-OCH3, (CH2)2-OCH(CH3)2, CH(CH2OH)(CH2CH(CH3)2), CH2CH(CH3)(OCH 3), CH 2 CH (N(CH 3 ) 2 ) (CH 2 CH 3 ), benzyl, methyl, ethyl, CH 2 -OCH 2 -CH 2-O-CH3, CH(CH3)C(O)N(CH3)2), C1-C5 substituted or unsubstituted linear or branched alkenyls, C1-C5 linear or branched or C3-C8 cyclic haloalkyls, C1-C5Substituted or unsubstituted linear or branched or C3-C8 cyclic alkoxys (e.g., methoxy, O-(CH2)2-O-CH3) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), C1-C5 linear or branched thioalkoxys, C1-C5 linear or branched haloalkoxys, C1-C5 linear or branched alkoxyalkyls, C3-C8 substituted or unsubstituted cycloalkyls (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R8-(C3-C8) substituted or unsubstituted cycloalkyls), substituted or unsubstituted 3- to 8-membered heterocycles (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3,3]heptane, imidazole, trifluoromethyl-oxetane, hydroxytetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryls, substituted or unsubstituted R8-aryls (e.g., benzyl), or substituted or unsubstituted benzyls; Alternatively, R6 and R5 may bond to each other to form a substituted or unsubstituted 5- to 8-membered heterocycle (e.g., azepane, piperazine, 2-(piperazine-1-yl)acetamide); Alternatively, R 6 can be represented by the following structural formula B or structural formula Bi: 【Chemistry 2】 During the ceremony, m is either 0 or 1; R12 is R20 or a C1-C5 C(O)-alkyl group, and R13 is R30; Alternatively, both R12 and R13 are H; Alternatively, R12 and R13 are independently H, or C1-C5 substituted or unsubstituted alkyl groups (e.g., ethyl, trifluoroethyl); Alternatively, R12 and C3 are bonded to each other to form an A ring, and R13 is R30; Alternatively, R12 and R13 may bond to each other to form a B ring; Alternatively, R12 and C1 are bonded to each other to form a C ring, and R13 is R30; Alternatively, C1 and C3 are bonded to each other to form a D ring, and R12 and R13 are R30 independently of each other; Alternatively, R13 and C2 are bonded to each other to form an E ring, m is 1, and R12 is R30; Alternatively, R12 and R13 may bond to each other to form a B ring, and C1 and C3 may bond to each other to form a D ring; Rings A, C, and E are independently substituted or unsubstituted, monocyclic, spirocyclic, or fused heterocyclic rings of 3 to 8 members (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methylazetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted, monocyclic, spirocyclic, or fused heterocyclic ring of 3 to 8 members (B: piperidine, piperidine-2-one, 4-fluoropiperidine-2-one, piperidine-4-carbonitride, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azabispiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is a C3-C8 substituted or unsubstituted cycloalkyl group (e.g., cyclobutane, cyclohexane); R7', R7'', R7'''', and R7'''''' are independently H, F, Cl, Br, I, OH, O-R20, SH, R8-OH, R8-SH, -R8-O-R10, R8-(C3-C8 cycloalkyl), R8-(3-8 membered heterocycle), CF3, CD3, OCD3, CN, NO2, -CH2CN, -R8CN, NH2, NHR, N(R)2, NH(R10), N(R10)(R11), R8-N(R10)(R11), R9-R8-N(R10) )(R 11), B(OH) 2, -OC(O)CF 3, -OCH 2 Ph, NHC(O)-R 10, NHCO-N(R 10)(R 11), COOH, -C(O)Ph, C(O)O-R 10, R 8-C(O)-R 10, C(O)H, C(O)-R 10, C1-C5 linear or branched C(O)-haloalkyl, -C(O)NH 2, C(O)NHR, C(O)N(R 10)(R 11), SO 2 R, SO 2 N(R 10)(R 11), CH(CF 3)(NH-R 10), C1-C5 Substituted or unsubstituted linear or branched alkyl groups (e.g., isopropyl, methyl, ethyl), C1-C5 substituted or unsubstituted linear or branched alkenyl groups, C1-C5 linear or branched or C3-C8 cyclic haloalkyl groups (e.g., CHF2), C1-C5 linear or branched or C3-C8 cyclic alkoxy groups (e.g., methoxy) (optionally, at least one methylene group (CH2) in the alkoxy is substituted with an oxygen atom), C1-C5 linear or branched thioalkoxy groups, C1-C5 linear or branched haloalkoxy groups, C1-C5 linear or branched alkoxyalkyl groups, C3-C8These are substituted or unsubstituted cycloalkyls (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic rings (e.g., morpholine, pyran, oxetane, pyrrolidine, imidazole, piperazine, piperidine, diaxazole, 2-oxopyrrolidine), substituted or unsubstituted aryls (e.g., phenyl), or substituted or unsubstituted benzyls; Alternatively, R7' and R7'' bond to each other to form substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic rings (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7'' and R7 bond to each other to form a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7 and R7'''' bond to each other to form substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic rings (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Alternatively, R7'' and R7'''' bond to each other to form substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic rings (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R20 is represented by the following structural formula: 【Transformation 3】 R 30 is H, R 20, F, Cl, Br, I, OH, SH, alkoxy, N(R) 2, NH(R 10), N(R 10)(R 11), CF 3, CN, NO 2, C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., methyl, ethyl, CH 2-CH 2-O-CH 2-CH 2-O-CH 3, CH 2-O-CH 2-CH 2-O-CH 3), C1-C5 linear or branched alkoxy, C1-C5 linear or branched haloalkyl (e.g., CHF 2, CF 3, CF 2 CH 3, CH 2 CF 3, CF 2 CH 2 CH 3) These are CH₂CH₂CF₃, CF₂CH(CH₃)₂, CF(CH₃)-CH(CH₃)₂, R₸-aryl (e.g., CH₂-Ph), -R₸-O-R₸-O-R₁₀ (e.g., (CH₂)₂-O-(CH₂)₂-O-CH₃), -R₸-O-R₁₀, -R₸-R₁₀ (e.g., (CH₂)₂-O-CH₃), substituted or unsubstituted aryls (e.g., phenyl), or substituted or unsubstituted heteroaryls (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R10), C(O)CH3, NH(R10), NH-CH2-cyclopropyl, N(R10)(R11), CF3, CN, NO2, C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., methyl, ethyl, iPr, CH2-cyclopropyl, CH2-OH, CH2-CH2-OH, CH2-CH2-O-CH2-CH2-O-CH3, CH2-O-CH2-CH2-O-CH3), C3-C8 substituted or unsubstituted cycloalkyl, cyclopropyl, C1-C5 Substituted or unsubstituted linear or branched alkoxys (e.g., methoxy, ethoxy, O-(CH2CH3), OCHF2, O-(CH2)2-O-CH3, isopropoxy, O-(CH2)-cyclopropyl, O-CH2-methylcyclobutyl, O-CH2-3-methyloxetane, O-CH(CH3)-CH2-O-CH3), C1-C5 linear or branched haloalkyls (e.g., CHF2, CF3, CF2CH3, CH2CF3, CF2CH2CH3, CH2CH2CF3, CF2CH(CH3)2, CF(CH3)-CH(CH3)2), R 8-aryl (e.g., CH2-Ph), -R8-O-R8-O-R10 (e.g., (CH2)2-O-(CH2)2-O-CH3), -R8-O-R10, O-R8-R10 (e.g., O-(CH2)2-O-CH3, O-(CH2CH3), O-(CH2)-cyclopropyl), -R8-R10 (e.g., (CH2)-cyclopropyl, (CH2)2-O-CH3, (CH2)-OH, (CH2)2-OH, (CH2 )-COOH), substituted or unsubstituted aryl (e.g., phenyl), or substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R 8 is independently [CH 2]p, where p is between 1 and 10 (e.g., 1, 2); R 9 is [CH] q or [C] q, where q is between 2 and 10; R10 and R11 are independently H, OH, COOH, C1-C5 substituted or unsubstituted linear or branched alkyl (e.g., methyl, ethyl, CH2-cyclopropyl, CH2-CH2-O-CH3), C3-C8 substituted or unsubstituted cycloalkyl (e.g., cyclopropyl), C1-C5 substituted or unsubstituted linear or branched haloalkyl (e.g., CH2CF3), C1-C5 linear or branched alkoxy (e.g., O-CH3), R20, C(O)R, or S(O)2R; Alternatively, R10 and R11 may bond to each other to form a substituted or unsubstituted 3- to 8-membered heterocycle (e.g., piperazine, piperidine); In the formula, n is an integer between 0 and 4 (for example, 1, 2).

2. The compound according to Claim 1, X 14 is either O or N; R1 is H, or R1 and R2 are bonded to each other to form a 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclopropyl, oxetane, pyrrolidine); R3 is either H, a C1-C5 substituted or unsubstituted alkyl group, or it is absent; R2 and R4 bond to each other to form an F ring (preferably pyrrolidine, piperidine, tetrahydrofuran, pyrrolidine-2-one, pyrrolidine-3-ol, or morpholine); R7' is either H or F; R5 is either H or CH3; R6 is H, a substituted or unsubstituted linear or branched alkyl group of C1-C5 (preferably methyl), a substituted or unsubstituted 3- to 8-membered heterocycle (preferably substituted or unsubstituted piperidine or tetrahydropyran), or R8-N(R10)(R11) (preferably (CH2)2-NH2, (CH2)3-NH2, (CH2)3-piperidine, or (CH2)3-4-fluoropiperidine), or R6 is represented by the structural formula Bi; Ring W is aromatic, and one of X2, X3, and X4 is C(R), where R is preferably an alkoxy and more preferably a methoxy; X12 is O, NH, N(R), CH=N, N=CH, CH=CH, OCH2, or N-OH, preferably R is a C1-C5 substituted or unsubstituted linear or branched alkyl, a C1-C5 substituted or unsubstituted linear or branched alkoxy, O-R8-R10, OH, NH(R10), haloalkoxy, or cycloalkyl; X4 is C(R), where R is an alkoxy, preferably a methoxy; R is CH2-COOH, CH2-CH2-OH, CH3, CH2CH3, iPr, cyclopropyl, or CH2-cyclopropyl; or, A compound, which is any combination of those compounds.

3. The compound according to claim 2, A compound in which R12 and R13 of the structural formula Bi are bonded to each other to form a substituted or unsubstituted piperidine ring, or R10 and R11 are bonded to each other to form a substituted or unsubstituted 3- to 8-membered heterocycle (e.g., piperidine or 4-fluoropiperidine).

4. The compound according to Claim 1, The compound represented by the following structural formula I(m), or its pharmaceutically acceptable salts, stereoisomers, tautomers, hydrates, N-oxides, reverse amide analogs, prodrugs, isotopic variants (e.g., deuterated analogs), pharmaceuticals, or any combination thereof. 【Chemistry 4】 During the ceremony, X 13 is CH 2, CH(R) (e.g., CH-CH 3), C(R) 2, or C=O; The G ring is either absent or is a substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic ring (e.g., cyclobutane, cyclopentane, cyclohexane); R 50 is H, R 20, F, Cl, Br, I, OH, SH, N(R) 2, NH(R 10), N(R 10)(R 11), CF 3, CN, NO 2, C1-C5 substituted or unsubstituted linear or branched alkyl, C1-C5 linear or branched alkoxy, C1-C5 linear or branched haloalkyl, -R 8-R 10 (e.g., (CH 2) 2-O-CH 3), substituted or unsubstituted aryl (e.g., phenyl), or substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)).

5. A compound according to claim 1 or 4, A compound represented by one of the structural formulas listed in the table below. Table 1-1 Table 1-2 Table 1-3 Table 1-4 Table 1-5

6. The compound represented by structural formula I(k) below, or its pharmaceutically acceptable salts, stereoisomers, tautomers, hydrates, N-oxides, reverse amide analogs, prodrugs, isotopic variants (e.g., deuterated analogs), PROTACs, pharmaceuticals, or any combination thereof. 【Transformation 5】 During the ceremony, The W ring can be an aromatic or aromatic ring. If the W ring is an aromatic ring, X ２ 、 X ３ 、 and X ４ are, independently of each other, CH, C(R), N (e.g., C(CH ３ ), C(O-CH ２ -cyclopropyl), C(O-CH ２ -methylcyclobutyl), C(O-CH ２ -3-methyloxetane), C(NH-CH ２ -cyclopropyl), C(isopropoxy), C(O-CH(CH ３ )-CH ２ -O-CH ３ ), C(CH ２ CH ３ ), C-iPr, C-CH ２ -cyclopropyl, C(OCH ３ ), C(OCH ２ CH ３ ), C(O-(CH ２ )) ２ -O-CH ３ ), C(OCHF ２ ), C(Cl), C(C(O)CH ３ ), C(O-CH ２ CH ２ -O-CH ３ ); X １５ C is; If the W ring is a non-aromatic ring, X ２ , X ３ , and X ４ CH ２ , CH(R), C(R) ２ NH, N(R), O, S, S=O, or SO ２ (For example, CH ２ ) is; X １５ is CH, C(R), or N (for example, CH, N); X ５ , X ６ , X ７ , X ８ , and X ９ These are, independently of each other, a nitrogen atom or a carbon atom. However, X ５ , X ６ , X ７ , X ８ , and X ９ If any one of them is nitrogen, then R ７ ', R ７ ´´、 R ７ , R ７ ´´´, and R ７ None of the substituents exist for ''''; X １０ is N, CH, C(R), or C=O. However, X １０ If C = O, then X １１ For example, N (C(CH) ２ -OH), C(CH ２ -CH ２ -OH), C(NH-CH ２ -Cyclopropyl), C(COOH), C(CH ３ ), C(cyclopropyl), C(isopropoxy)); X １１ is N or C. However, X １１ If X is N, １０ C = O; The W' ring can be an aromatic or aromatic ring. If the W' ring is an aromatic ring, X １２ S, SO ２ O, NH, N(R), N-OH, CH=CH, CH=CH(R), C(R)=CH, N=CH, N=C(R), CH=N, or C(R)=N (for example, N-CH ２ -COOH,N-CH ２ -CH ２ -OH, N-CH ３ N-CH ２ CH ３ N-iPr, N-cyclopropyl, N-CH ２ -Cyclopropyl) If the W' ring is a non-aromatic ring, X １２ are CH=CH, CH=CH(R), C(R)=CH, OCH ２ SCH ２ CH=N, C(R)=N, N=CH, or N=C(R); If both the W ring and the W ring' are aromatic rings, X ２ , X ３ , and X ４ At least one of them is C(R); X １１ is N; or X １２ It is not S; R ５ is H, or C １ -C ５ It is a linear or branched alkyl group (e.g., methyl); R ６ is H, F, Cl, Br, I, OH, SH, R ８ -OH, R ８ -SH, -R ８ -O-R １０ (e.g., CH ２ -O-CH ３ , (CH ２ ) ２ -O-CH ３ , (CH ２ ) ３ -O-CH ３ , (CH ２ ) ２ -O-CH(CH ３ ) ２ ), R ８ -S-R １０ (e.g., (CH ２ ) ３ -S-(CH ２ ) ２ CH ３ ), R ８ -NH-C(O)-R １０ , -O-R ８ -R １０ , R ８ -(C ３ -C ８ of substituted or unsubstituted cycloalkyl) (e.g., CH ２ -cyclopropyl, CH ２ -cyclobutanol, CH ２ -difluorocyclopropyl, CH ２ -methylcyclopropyl, CH ２ -dimethylamino-cyclohexyl, (CH ２ ) ２ -cyclopentanol, CH ２ -cyclohexanol), R ８ -(substituted or unsubstituted, saturated, unsaturated, or aromatic, monocyclic, fused-ring, or spiro-ring 3- to 10-membered heterocyclic ring) (e.g., (CH ２ ) ３ -piperidine, (CH ２ ) ３ -4-fluoropiperidine, (CH ２ ) ３ -pyran, (CH ２ ) ２ -pyrazole, (CH ２ ) ２ - Imidazole, CH ２ - Tetrahydrofuran, CH ２ - Dioxane, CH ２ - Oxetane, CH ２ - Piperidine, CH ２ - Triazole, CH ２ -1-oxa-8-azaspiro[4.5]decane, (CH ２ ) ３ - Diazabicyclo[2.2.1]heptane, CH ２ -methyl-THF,CH ２ -Ethyl-piperidine, CH ２ -Oxa-azaspirodecane, (CH ２ ) ３ - Dimethylpyrazole, CH ２ -2-oxo-methylpyrrolidine, CH ２ -Methyl-azetidine, CH ２ - Azaspiroheptane), CF ３ CD ３ OCD ３ , CN, NO ２ ien-CH ２ CN, -R ８ CN, NH ２ NHR, N(R) ２ NH(R １０ ), N (R １０ ) (Caution １１ ), R ８ -N(R) １０ ) (Caution １１ ) (For example, (CH ２ ) ２ -NH ２ , (CH ２ ) ３ -N(CH ２ CH ３ ) ２ , (CH ２ ) ３ -N(CH(CH ３ ) ２ ) ２ , (CH ２ ) ３ -Piperidine, (CH ２ ) ３ -4-Fluoropiperidine, (CH ２ ) ３ -4-cyano-piperidine, (CH ２ ) ４ -NH(CH ３ ), (CH ２ ) ３ -NH-CH ３ , (CH ２ ) ３ -NH-CH ２ CH ３ , (CH ２ ) ３ -N(CH ２ CH ３ ) ２ , (CH ２ ) ３ -NH ２ , (CH ２ ) ３ -N(CH ２ CH ３ ) (CH ２ CF ３ )), R ９ -R ８ -N(R) １０ ) (Caution １１ ) (For example, (CH ２ ) ２ -C(O)-piperidine), B(OH) ２ -OC(O)CF ３ , -OCH ２ Ph, NHC(O)-R １０ NHCO-N(R １０ ) (Caution １１ ), COOH, -C(O)Ph, C(O)OR １０ , R ８ -C(O)-R １０ , C(O)H, C(O)-R １０ (For example, C(O)CH ３ ), C １ -C ５ Linear or branched C(O)-haloalkyl, -C(O)NH ２ , C(O)NHR, C(O)N(R １０ ) (Caution １１ ), SO ２ R, SO ２ N(R) １０ ) (Caution １１ ), CH(CF ３ ) (NH-R １０ ), C １ -C ５ Substituted or unsubstituted linear or branched alkyl groups (e.g., CH(CH) ３ )CH ２ OCH ３ , CH (CH ３ )CH ２ NH ２ , CH (CH ３ ) C(O)N(CH ３ ) ２ ,CH ２ -CH(OH)Ph, (CH ２ ) ３ N(H)CH ２ CH ３ , CH (CH ３ ) (CH ２ ) ２ OH, CH(CH ２ OH) (CH ２ CH ３ ), (CH ２ ) ３ - OCH ３ , (CH ２ ) ２ - OCH ３ , (CH ２ ) ２ - OCH(CH ３ ) ２ , CH (CH ２ OH) (CH ２ CH (CH ３ ) ２ ), CH ２ CH (CH ３ ) (OCH ３ ), CH ２ CH(N(CH ３ ) ２ ) (CH ２ CH ３ ), benzyl, methyl, ethyl, CH ２ - OCH ２ -CH ２ -O-CH ３ , CH (CH ３ ) C(O)N(CH ３ ) ２ ), C １ -C ５ Substituted or unsubstituted linear or branched alkenyls, C １ -C ５ A straight chain or a branched chain or C ３ -C ８ A cyclic haloalkyl, C １ -C ５ Substituted or unsubstituted linear or branched chains of C ３ -C ８ cyclic alkoxys (e.g., methoxy, O-(CH)) ２ ) ２ -O-CH ３ ) (Optionally, at least one methylene group (CH) in the alkoxy ２ ) is replaced by an oxygen atom), C １ -C ５ Linear or branched thioalkoxys of C １ -C ５ Linear or branched haloalkoxys, C １ -C ５ Linear or branched alkoxyalkyl groups, C ３ -C ８ Substituted or unsubstituted cycloalkyls (e.g., cyclopropyl, cyclobutyl, cyclohexyl, methoxycyclopropyl, methylcyclobutyl, aminomethyl-cyclobutyl, methoxycyclobutyl, 2,3-dihydro-1H-indenol), R ８ - (C ３ -C ８ Substituted or unsubstituted cycloalkyls), substituted or unsubstituted 3- to 8-membered heterocycles (e.g., piperidine, 1-methylpiperidine, azetidine, pyrrolidine, pyrrolidinone, quinuclidine, tetrahydropyran, azaspiro[3,3]heptane, imidazole, trifluoromethyl-oxetane, hydroxytetrahydrofuran, azepan-2-one, azabicyclohexane), substituted or unsubstituted aryls, substituted or unsubstituted R ８ - Aryl (e.g., benzyl), or substituted or unsubstituted benzyl; Or, R ６ and R ５ These combine with each other to form substituted or unsubstituted 5- to 8-membered heterocycles (e.g., azepane, piperazine, 2-(piperazine-1-yl)acetamide); Or, R ６ It is represented by the following structural formula B or structural formula Bi: 【Transformation 6】 During the ceremony, m is either 0 or 1; R １２ R ２０ , or C １ -C ５ It is a C(O)-alkyl group, and R １３ R ３０ It is; Or, R １２ and R １３ Both are H; Or, R １２ and R １３ These are H or C, independently of each other. １ -C ５ It is a substituted or unsubstituted alkyl (e.g., ethyl, trifluoroethyl); Or, R １２ And C3 are bonded to each other to form an A ring, R １３ is R ３０ It is; Or, R １２ and R １３ They bond to each other to form a B ring; Or, R １２ And C1 are bonded to each other to form a C ring, R １３ is R ３０ It is; Alternatively, C1 and C3 are bonded to each other to form a D ring, R １２ and R １３ R is independent of each other. ３０ It is; Or, R １３ And C2 are bonded to each other to form an E ring, m is 1, R １２ is R ３０ It is; Or, R １２ and R １３ These atoms bond to each other to form a B ring, and C1 and C3 bond to each other to form a D ring; Rings A, C, and E are independently substituted or unsubstituted, monocyclic, spirocyclic, or fused heterocyclic rings of 3 to 8 members (e.g., A: pyrrolidine, methylpyrrolidine, ethylpyrrolidine; C: piperidine, pyrrolidine, methyl-2-oxopyrrolidine, pyran-pyrrolidine, methylazetidine, azabicyclooctane, 2-azabicyclo[2.1.1]hexane, 2-azaspiro[3.3]heptane; E: pyrrolidine, azetidine, ethylpyrrolidine, oxopyrrolidine, methylpiperidine); Ring B is a substituted or unsubstituted, monocyclic, spirocyclic, or fused heterocyclic ring of 3 to 8 members (B: piperidine, piperidine-2-one, 4-fluoropiperidine-2-one, piperidine-4-carbonitride, 4-fluoropiperidine, 4-fluoro-2-methylpiperidine, methyl-piperidine, fluoropiperidine, difluoropiperidine, pyrrolidine, piperazine, methylpyrrolidine, thiomorpholine 1,1-dioxide, 2-oxa-6-azabispiro[3.3]heptane, methyl-piperazine, dimethylpyrazole, imidazole, 2-methyl-2,5-diazabicyclo[2.2.1]heptane, hydroxymethyl-pyrrolidine, diazabicyclo[2.2.1]heptane, 6-fluoro-3-azabicyclo[3.1.1]heptane); The D ring is C ３ -C ８ These are substituted or unsubstituted cycloalkyls (e.g., cyclobutane, cyclohexane); R ７ These are H, F, Cl, Br, I, OH, O-R ２０ SH, R ８ -OH, R ８ -SH, SR １０ , -R ８ -O-R １０ , -R ８ -S-R １０ , R ８ - (C ３ -C ８ Cycloalkyl), CF ３ CD ３ OCD ３ , CN, NO ２ ien-CH ２ CN, -R ８ CN, NH ２ NHR, N(R) ２ NH(R １０ ), N (R １０ ) (Caution １１ ), R ８ -N(R) １０ ) (Caution １１ ), R ９ -R ８ -N(R) １０ ) (Caution １１ ), B (OH) ２ -OC(O)CF ３ , -OCH ２ Ph, NHC(O)-R １０ NHCO-N(R １０ ) (Caution １１ ), COOH, -C(O)Ph, C(O)OR １０ , R ８ -C(O)-R １０ , C(O)H, C(O)-R １０ , C １ -C ５ Linear or branched C(O)-haloalkyl, -C(O)NH ２ , C(O)NHR (for example, C(O)NH(CH ３ )), C(O)N(R １０ ) (Caution １１ ) (For example, C(O)NH(CH ３ ), C(O)NH(CH ２ CH ２ OCH ３ ), C(O)NH(CH ２ CH ２ OH)), SO ２ R, SO ２ N(R) １０ ) (Caution １１ ), CH(CF ３ ) (NH-R １０ ), C １ -C ５ Substituted or unsubstituted linear or branched alkyl groups (e.g., methylimidazole, methyl, ethyl), C １ -C ５ Substituted or unsubstituted linear or branched alkenyls, C １ -C ５ A straight chain or a branched chain or C ３ -C ８ cyclic haloalkyl (e.g., CHF) ２ ), C １ -C ５ A straight chain or a branched chain or C ３ -C ８ A cyclic alkoxy (e.g., methoxy, ethoxy) (optionally, at least one methylene group in the alkoxy (CH) ２ ) is replaced by an oxygen atom), C １ -C ５ A straight-chain or branched-chain thioalkyl, C １ -C ５ Linear or branched thioalkoxys of C １ -C ５ Linear or branched haloalkoxys, C １ -C ５ Linear or branched alkoxyalkyl groups, C ３ -C ８ Substituted or unsubstituted cycloalkyl compounds (e.g., cyclopropyl, cyclopropanol, cyclohexyl), substituted or unsubstituted 4- to 7-membered heterocyclic rings (e.g., morpholine, (e.g., 2 or 3-morpholine), tetrahydropyran, tetrahydropyran, oxetane, oxetane-3-ol, pyrrolidine, pyrrolidine-3-ol, 1-methylpyrrolidine, pyrrolidine-2-one, pyrrolidinone, imidazole, pyrazole, piperazine, piperidine, piperidine-4-ol, piperidine-4-carbonitride, 4-fluoropiperidine, oxadiazole, triazole, 2-oxopyrrolidine, pyridine, 1-methylpyridine), R ８ - (substituted or unsubstituted, monocyclic, fused, or spirocyclic heterocyclic rings of 3 to 8 members), substituted or unsubstituted aryl, or substituted or unsubstituted benzyl; R ７ ', R ７ ´´、 R ７ ´´´, and R ７ '''' are independent of each other: H, F, Cl, Br, I, OH, O-R ２０ SH, R ８ -OH, R ８ -SH, -R ８ -O-R １０ , R ８ - (C ３ -C ８ Cycloalkyl), R ８ - (Heterogeneous rings of 3 to 8 members), CF ３ CD ３ OCD ３ , CN, NO ２ ien-CH ２ CN, -R ８ CN, NH ２ NHR, N(R) ２ NH(R １０ ), N (R １０ ) (Caution １１ ), R ８ -N(R) １０ ) (Caution １１ ), R ９ -R ８ -N(R) １０ ) (Caution １１ ), B (OH) ２ -OC(O)CF ３ , -OCH ２ Ph, NHC(O)-R １０ NHCO-N(R １０ ) (Caution １１ ), COOH, -C(O)Ph, C(O)OR １０ , R ８ -C(O)-R １０ , C(O)H, C(O)-R １０ , C １ -C ５ Linear or branched C(O)-haloalkyl, -C(O)NH ２ , C(O)NHR, C(O)N(R １０ ) (Caution １１ ), SO ２ R, SO ２ N(R) １０ ) (Caution １１ ), CH(CF ３ ) (NH-R １０ ), C １ -C ５ Substituted or unsubstituted linear or branched alkyl groups (e.g., isopropyl, methyl, ethyl), C １ -C ５ Substituted or unsubstituted linear or branched alkenyls, C １ -C ５ A straight chain or a branched chain or C ３ -C ８ cyclic haloalkyl (e.g., CHF) ２ ), C １ -C ５ A straight chain or a branched chain or C ３ -C ８ A cyclic alkoxy (e.g., methoxy) (optionally, at least one methylene group (CH) in the alkoxy) ２ ) is replaced by an oxygen atom), C １ -C ５ Linear or branched thioalkoxys of C １ -C ５ Linear or branched haloalkoxys, C １ -C ５ Linear or branched alkoxyalkyl groups, C ３ -C ８ These are substituted or unsubstituted cycloalkyls (e.g., cyclopropyl, cyclohexyl), substituted or unsubstituted 3- to 8-membered heterocyclic rings (e.g., morpholine, pyran, oxetane, pyrrolidine, imidazole, piperazine, piperidine, diaxazole, 2-oxopyrrolidine), substituted or unsubstituted aryls (e.g., phenyl), or substituted or unsubstituted benzyls; Or, R ７ ' and R ７ These atoms bond to each other to form substituted or unsubstituted, saturated, unsaturated, or aromatic, 3- to 8-membered carbocyclic or heterocyclic rings (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Or, R ７ ´´ and R ７ These combine with each other to form substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic rings (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Or, R ７ and R ７ These atoms bond to each other to form substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic rings (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); Or, R ７ ´´´ and R ７ These elements bond to each other to form substituted or unsubstituted 3- to 8-membered carbocyclic or heterocyclic rings (e.g., cyclopentyl, cyclohexyl, piperidine, tetrahydrofuran, tetrahydropyran, pyrrolidine); R ２０ It is represented by the following structural formula: 【Transformation 7】 R ３０ H, R ２０ F, Cl, Br, I, OH, SH, alkoxy, N(R) ２ NH(R １０ ), N (R １０ ) (Caution １１ ), CF ３ , CN, NO ２ , C １ -C ５ Substituted or unsubstituted linear or branched alkyl groups (e.g., methyl, ethyl, CH) ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ ,CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C １ -C ５ Linear or branched alkoxy, C １ -C ５ A linear or branched haloalkyl group (e.g., CHF) ２ CF ３ CF ２ CH ３ ,CH ２ CF ３ CF ２ CH ２ CH ３ ,CH ２ CH ２ CF ３ CF ２ CH (CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ - Aryl (for example, CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (For example, (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ , -R ８ -R １０ (For example, (CH ２ ) ２ -O-CH ３ ), substituted or unsubstituted aryls (e.g., phenyl), or substituted or unsubstituted heteroaryls (e.g., pyridine (2,3,4-pyridine)); R is H, F, Cl, Br, I, OH, SH, COOH, CO(R １０ ), C(O)CH ３ NH(R １０ ), NH-CH ２ -Cyclopropyl, N(R １０ ) (Caution １１ ), CF ３ , CN, NO ２ , C １ -C ５ Substituted or unsubstituted linear or branched alkyl groups (e.g., methyl, ethyl, iPr, CH) ２ -Cyclopropyl, CH ２ -OH, CH ２ -CH ２ -OH, CH ２ -CH ２ -O-CH ２ -CH ２ -O-CH ３ ,CH ２ -O-CH ２ -CH ２ -O-CH ３ ), C ３ -C ８ Substituted or unsubstituted cycloalkyl, cyclopropyl, C １ -C ５ Substituted or unsubstituted linear or branched alkoxys (e.g., methoxy, ethoxy, O-(CH)) ２ CH ３ ), OCHF ２ , O-(CH ２ ) ２ -O-CH ３ Isopropoxy, O-(CH ２ )-Cyclopropyl, O-CH ２ -Methylcyclobutyl, O-CH ２ -3-methyloxetane, O-CH(CH ３ ) - CH ２ -O-CH ３ ), C １ -C ５ A linear or branched haloalkyl group (e.g., CHF) ２ CF ３ CF ２ CH ３ ,CH ２ CF ３ CF ２ CH ２ CH ３ ,CH ２ CH ２ CF ３ CF ２ CH (CH ３ ) ２ , CF(CH ３ )-CH(CH ３ ) ２ ), R ８ - Aryl (for example, CH ２ -Ph), -R ８ -O-R ８ -O-R １０ (For example, (CH ２ ) ２ -O-(CH ２ ) ２ -O-CH ３ ), -R ８ -O-R １０ O-R ８ -R １０ (For example, O-(CH ２ ) ２ -O-CH ３ , O-(CH ２ CH ３ ), O-(CH ２ )-Cyclopropyl),-R ８ -R １０ (For example, (CH ２ )-cyclopropyl, (CH ２ ) ２ -O-CH ３ , (CH ２ )-OH, (CH ２ ) ２ -OH, (CH ２ )-COOH), substituted or unsubstituted aryl (e.g., phenyl), or substituted or unsubstituted heteroaryl (e.g., pyridine (2,3,4-pyridine)); Each R ８ [CH ２ ] ｐ And p is between 1 and 10 (for example, 1, 2); R ９ is [CH] ｑ , or [C] ｑ And q is between 2 and 10; R １０ and R １１ These are H, OH, COOH, and C, which are independent of each other. １ -C ５ Substituted or unsubstituted linear or branched alkyl groups (e.g., methyl, ethyl, CH) ２ -Cyclopropyl, CH ２ -CH ２ -O-CH ３ ), C ３ -C ８ Substituted or unsubstituted cycloalkyls (e.g., cyclopropyl), C １ -C ５ Substituted or unsubstituted linear or branched haloalkyl groups (e.g., CH ２ CF ３ ), C １ -C ５ Linear or branched alkoxys (e.g., O-CH ３ ), R ２０ , C(O)R, or S(O) ２ It is R; Or, R １０ and R １１ These combine with each other to form substituted or unsubstituted 3- to 8-membered heterocycles (e.g., piperazine, piperidine); In the formula, n is an integer between 0 and 4 (for example, 1, 2).

7. The compound according to claim 6, R ７ H, C(O)N(R) １０ ) (Caution １１ ) (preferably C(O)NH(CH ３ )), C １ -C ５ A substituted or unsubstituted linear or branched alkyl group (preferably methyl), C ３ -C ８ The substituted or unsubstituted cycloalkyl (preferably cyclopropanol), the substituted or unsubstituted 4- to 7-membered heterocycle (preferably morpholine, pyrrolidine, pyrrolidine-3-ol, piperidine, piperidine-4-ol, tetrahydrofuran, oxetane, oxetane-3-ol, pyridine, or 1-methylpyridine), or the substituted or unsubstituted aryl; R7' is either H or F; R ５ is H or CH ３ It is; R ６ H, C １ -C ５ A substituted or unsubstituted linear or branched alkyl group (preferably methyl), a substituted or unsubstituted 3- to 8-membered heterocycle (preferably substituted or unsubstituted piperidine or tetrahydropyran), or R ８ -N(R) １０ ) (Caution １１ ) (preferably (CH ２ ) ２ -NH ２ , (CH ２ ) ３ -NH ２ , (CH ２ ) ３ -Piperidine, or (CH ２ ) ３ -4-fluoropiperidine) or R ６ This is represented by the structural formula Bi; Ring W is aromatic, and one of X2, X3, and X4 is C(R), where R is preferably an alkoxy and more preferably a methoxy; X12 is O, NH, N(R), CH=N, N=CH, CH=CH, OCH2, or N-OH, preferably R is a C1-C5 substituted or unsubstituted linear or branched alkyl, a C1-C5 substituted or unsubstituted linear or branched alkoxy, O-R8-R10, OH, NH(R10), haloalkoxy, or cycloalkyl; X4 is C(R), where R is an alkoxy, preferably a methoxy; R is CH2-COOH, CH2-CH2-OH, CH3, CH2CH3, iPr, cyclopropyl, or CH2-cyclopropyl; or, A compound, which is any combination of those compounds.

8. A compound according to claim 1 or 6, A compound represented by one of the structural formulas listed in the table below. Table 2-1 Table 2-2 Table 2-3 Table 2-4 Table 2-5

9. A compound represented by one of the structural formulas listed in the table below. Table 3

10. A compound according to claim 1 or 6, The compound in question is a compound that is substantially a single, pure stereoisomer.

11. A compound according to claim 1 or 6, The compound is a c-MYC mRNA translation regulator, a c-MYC mRNA transcription regulator, a c-MYC inhibitor, or any combination thereof.

12. A compound according to claim 1 or 6, A pharmaceutical composition comprising a pharmaceutically acceptable carrier.

13. A compound according to claim 1 or 6, Compounds for use in the treatment, suppression, reduction of severity, reduction of risk of developing, or inhibition of cancer in a given subject.

14. The compound according to claim 13, The aforementioned cancers are selected from the group consisting of breast cancer, ovarian cancer, acute myeloid leukemia, chronic myeloid leukemia, Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, prostate cancer, colon cancer, gastric cancer, primary central nervous system lymphoma, glioblastoma, medulloblastoma, melanoma, non-small cell lung cancer, germinal center-derived lymphoma, esophageal squamous cell carcinoma, osteosarcoma, bladder cancer, pancreatic cancer, lung adenocarcinoma, BRAFV600E thyroid cancer, choroid plexus cancer, colitis-related cancer, epithelial ovarian cancer, colorectal cancer, pancreatic cancer, and uterine cancer. The aforementioned cancer is early-stage cancer, advanced cancer, invasive cancer, metastatic cancer, drug-resistant cancer, or any combination thereof. The subject has previously received treatment with chemotherapy, immunotherapy, radiotherapy, biological therapy, surgical intervention, or any combination thereof. The compound is administered in combination with anticancer therapy, or A compound, which is any combination of those compounds.

15. The compound according to claim 14, The aforementioned anti-cancer therapy is a compound, which may be chemotherapy, immunotherapy, radiotherapy, biological therapy, surgical intervention, or any combination thereof.

16. A compound according to claim 1 or 6, Compounds used for suppressing, reducing, or inhibiting tumor growth in a target.

17. A method for regulating c-MYC mRNA translation or c-MYC mRNA transcription in cells, A method comprising the step of contacting a cell with a compound according to claim 1 or 6, thereby regulating c-MYC mRNA translation or c-MYC mRNA transcription in the cell.

18. The method according to claim 17, This method is By regulating c-MYC mRNA splicing (inclusion or exclusion of untranslated regions, or alternative use of exons), By regulating c-MYC mRNA modification, By regulating the interaction between RNA-binding proteins and c-MYC mRNA, thereby altering mRNA localization, By regulating the localization of c-MYC mRNA in the cytoplasm, By regulating ribosomes and ribosomal cofactors in relation to c-MYC mRNA, By reducing the amount of c-MYC protein in cells, Or, a method that is carried out by any combination thereof.

Images